CUMULATIVE INDEX 2000

Volume 29

March	ENDOCRINE INCIDENTALOMAS, pages 1–238
June	AUTOIMMUNE THYROID DISEASE, pages 239–449
September	HORMONES AND DISORDERS OF MINERAL METABOLISM, pages 451–655
December	ACUTE COMPLICATIONS OF DIABETES, pages 657–872

Note: Page numbers of article titles are in **boldface** type

Acetazolamide, for tumor calcinosis, 605
Acetest tablet testing, for ketone bodies, 664
Acetoacetate, in diabetic ketoacidosis, 664, 687–688, 693, 697
  in type 1 diabetes monitoring, 710
Acetone, in diabetic ketoacidosis, 710
Acid-base disturbances. See also *specific type.*
  with diabetic ketoacidosis, 687–689
    correction of, 696–697
    evaluation of, 692–693
    in children, 661
      cerebral edema from, 677–678
      compensatory mechanisms for, 661–664
      management guidelines for, 668–671, 674
  with hyperglycemic hyperosmolar nonketotic syndrome, 688, 690, 697
Acromegaly, with adrenal pathology, 206, 216, 227
Acupuncture, for Graves' ophthalmopathy, 315
Acute illness, hyperglycemic disorders with, 691–692, 698–699
    type 1 diabetes sick-days and, 707–708, 719–720
  metabolic stress responses with, glycemic control and, 745–747
Adenomas. See *specific anatomy.*
Adipogenesis, in orbit, with Graves' disease, 289–290, 292
Adolescents, Graves' disease in, 329–330, 347, 440
Adrenal adenomas, benign, 40–41, 45, 128, 136
  differential diagnosis of, 127–130, 162–163, 170–171
    imaging techniques for, 30–33, 39
  malignant. See *Adrenal cancer.*
  pathogenesis of, 1, 3–4
  prevalence of, 162–163
  surgical management of, 109, 133–134, 179
Adrenal calcification, 37
Adrenal cancer, **15–25**
  clinical presentations of, 18–20, 116–117, 132–133, 144–145
  diagnosis of, 116–120, 151–152
    biopsy techniques for, 35, 118–119, 135–136, 152
    hormonal tests for, 20
    imaging techniques for, 20, 39–41, 59, 117–118, 151, 169–172
    molecular studies for, 16–18, 118–119, 135–136, 152
    per size, 59, 117–118, 131–134, 151
  differential diagnosis of, 116–120, 151–152, 166, 175
  epidemiology of, 15–16
  metastasis of, 20–21
  metastatic, adrenal incidentaloma vs., 151–152, 166, 170, 173, 175–176
    aspiration biopsies of, 35, 118–119, 135–136
    features of, 118, 144–145
    imaging techniques for, 30–33, 39–40
  molecular genetics of, 16–18, 118–119, 135–136, 152
  pathophysiology of, 20–21

Adrenal cancer *(Continued)*
prevalence of, 1, 9, 15–16, 116–117
tumor size and, 131–134
primary, case examples of, 132–133
curative resections for, 59, 132
diagnostic techniques for, 116–120, 131–132, 151–152
features of, 132–133, 144–145
imaging techniques for, 39–41, 59, 151
probabilities per tumor size, 59, 117–118, 131–134, 151
risks with silent mass, 134–135
prognosis of, 21–22
secondary, features of, 144–145
staging of, 20–21
treatment of, 21
Adrenal crisis, 47, 53, 113
Adrenal cryotherapy, 65
Adrenal cysts, clinical presentations of, 59, 142–143
radiologic evaluation of, 30, 35–36
Adrenal function tests, 227
Adrenal glands, radiology of, **27–42**
incidentaloma discovery by, 1, 27, 57, 69, 127, 136–138, 141, 146, 160
normal views of, 28, 34, 39
plain abdominal radiographs, 29
preoperative indications, 58
serial follow-up guidelines, 59, 121, 136–137, 153–154, 180
surgery of, **57–68**
Adrenal hemorrhage, 30–31, 35–36
Adrenal hyperplasia, congenital (CAH), screening tests for, 129, 168–169
macronodular, adrenocorticotropic hormone-independent, 3–6, 44–45
incidentalomas and, 3–4
molecular genetics of, 16–17
Adrenal incidentalomas, **159–185**
definition and history of, 69, 108–109, 120, 159
diagnosis of, **69–90**
algorithmic approach for, 27, 40, 120–121, 178–179
autopsy examinations, 146, 161–162, 164, 176
Bayesian approach example, 99–101
computed tomography for, 27–32, 35–41, 147, 160–163, 169–174
cost-effectiveness analysis, 71–73, 78, 80–83, 89–90
functional status and, 108–116, 146–149, 162–174, 178–179
hormone tests for, 108–116, 148–151, 164, 166–169
magnetic resonance imaging for, 27, 32–33, 58, 169–172
malignant potential and, 116–120, 162, 169–178
molecular approach to, 9–10
positron emission tomography, 33, 120
scintigraphy for, 33–34, 148–149, 151, 176, 178
surgical evaluations, 164–166
through imaging, 1, 27, 57, 69, 127, 136–138, 141, 146, 160
ultrasonography for, 20, 29, 135
diagnostic-therapeutic strategies analysis, cost-effectiveness, 71–74, 78, 80–83, 89–90
preliminary diagnosis outcomes, 77–80
quality-adjusted life expectancy, 70–83, 89–90
reference case scenario outcomes, 74–77
differential diagnosis of, cancer vs., 116–120, 151–152, 166, 175
Cushing's syndrome vs., 146, 148, 164–167, 173
pheochromocytoma vs., 146, 148–150, 166, 168, 170–172, 176
primary aldosteronism vs., 149, 151, 166, 168
follow-up recommendations, algorithms for, 121, 138, 178
hormonal, 111, 154, 179–180
serial imaging, 59, 121, 136–137, 153–154, 180
functional status, assessment of, goals for, 27, 146–148
hormone tests for, 108–116, 148–151, 164, 166–169
other active hormone processes, 166, 168–169
overview of, 40, 162–164, 166
techniques for, 108–116, 170–174, 178–179
Italian Society of Endocrinology study of, 107–125
malignant. See *Adrenal cancer.*
malignant potential, assessment of, fine-needle aspiration biopsy, 35, 118–119, 174–177
imaging phenotype, 117–118, 169–174
mass size, 118, 175
meta-analysis, 70–73
overview of, 40, 116–117, 162, 169
scintigraphy, 119–120, 176–178
management of, algorithmic approach for, 40, 108, 120–121, 155, 178–179
cost-effectiveness analysis, 70–83, 89–90, 120
evidence-based guidelines, 82–83
functional status and, 108–116, 146–149, 162–174, 178–179
Italian views on, **107–125**
malignant potential and, 116–120, 162, 169–178
personal view on, **141–157**
quality-adjusted life-years analysis, 70–83, 89–90

surgical, **57–68,** 71, 120, 146–147, 150, 152–154, 179
pathogenesis of, **1–13**
11p15 chromosome region and, 5–8
clonal analysis, 3–4
growth factors overexpression, 4–8
membrane signaling pathways role, 4–6
oncogenes, 8–9
tumor suppressor genes, 8–9
prevalence of, 69, 107–108, 161–163
quality-adjusted life expectancy analysis, of diagnostic-therapeutic strategies, 70–83, 89–90
of untreated tumors, 70–75, 89–90
surgical management of, **57–68**
cost-effectiveness analysis, 70–74, 78–79, 81–83
indications for, 21, 54, 64, 120–121, 152–153
laparoscopic, 52, 60–64, 150, 152, 154, 179
open (conventional), 61–64, 146–147, 154
postoperative care, 53, 64
preoperative considerations, 47, 54, 57–60, 120
recent developments in, 65
treatment of, 40, **69–90**
cost-effectiveness analysis, 70–83, 89–90, 120
types of, 141–146
underlying disorders, meta-analysis, 70–71
untreated, cost-effectiveness analysis, 70, 74–75, 80–83, 89–90
quality-adjusted life expectancy analysis, 70–75, 89–90
Adrenal lesions. See *Adrenal masses.*
Adrenal masses, incidentally discovered. See also *Adrenal incidentalomas.*
algorithmic management of, 108, 120–121, 136–138
case examples of, 128–129, 132–133
evaluation of, **127–139**
radiologic techniques for, 30–31, 35–40
extra-adrenal neoplasms with, 136
hormone secretion by, 127–131
malignancy risks with. See also *Adrenal neoplasms.*
evaluation techniques for, 131–132, 135–136
per mass size, 131–134
with silent masses, 134–135
prevalence of, 44, 107
surgical removal of, indications for, 133–134, 136–138
treatment options for, 40–41, 133
Adrenal neoplasms, diagnosis of, molecular approaches to, 9–10
differential diagnosis of, 166, 170–178
genetic syndromes associated with, **1–13**
malignant. See *Adrenal cancer.*
sporadic. See *Adrenal incidentalomas.*
Adrenalectomy, bilateral, 61
cost-effectiveness analysis, 70–74, 78–79, 81–83
endoscopic, 52
indications for, 21, 52, 54, 120–121, 152–153
laparoscopic, indications for, 29, 52, 64, 120, 150, 152, 154, 179
morbidity of, 59
open vs., 62–64
techniques for, 60–61
open, indications for, 64, 146–147, 154
laparoscopic vs., 62–64
techniques for, 61–62
postoperative considerations, 47, 53, 64, 113
preoperative considerations, fine-needle aspiration cytology, 59
history and examination, 57–58, 120
hormonal evaluation, 47, 54, 58, 120
malignancy risk determinations, 59
patient preparation, 59–60
radiographic evaluation, 58, 120
subtotal, 65
techniques for, comparison of, 62–64
laparoscopic, 60–61
open, 61–62
selection criteria, 64, 179
ultrasound monitoring during, 29, 61
unilateral, 45, 60–61, 113
Adrenalomas. See *Adrenal incidentalomas.*
b-Adrenergic antagonists. See *Beta-blockers.*
b-Adrenergic receptors, adrenal incidentalomas and, 6, 9
Adrenocortical tumors, in MEN–1 syndrome, 542–544, 549
Adrenocorticotropic hormone (ACTH), adrenal incidentalomas and, 3–6, 109, 112, 127, 146, 164, 167, 173–174
Cushing's syndrome and, 44–45, 47–48, 50, 109–112
pituitary incidentalomas and, 205, 207–208, 212–213
Age, as parathyroidectomy indication, 472, 475, 491
Alanine aminotransferase (ALT), thiazolidinediones impact on, 808–809
Albright's hereditary osteodystrophy (AHO), hormone resistance and, 571–574
inheritance patterns of, 577–578, 584
Alcohol intake, in diabetic patients, 662, 692
hypoglycemia with, 738, 796, 805
Aldosterone, increased levels of, with diabetic ketoacidosis, 660

Aldosterone-producing adenoma (APA), 115, 166, 168
Aldosteronism, primary, adrenal incidentaloma vs., 149, 151, 166, 168
hallmark features of, 115, 149
Aldosteronomas, 65, 115, 142–143, 146, 151
Alkaline phosphate levels, with hyperparathyroidism, 484
with vitamin D deficiency, 614, 617, 620
Allele analysis, in Graves' disease, 257–263
in Hashimoto's disease, 359–360, 364–365, 367–368
Alopecia, with rickets, 619–620
Alpha-glucosidase inhibitors, for diabetic patients, during hospitalization, 755, 761
nonhypoglycemic reactions with, 807–808
American endocrinologists, on pituitary incidentaloma, management survey, 223–229
test ordering practices, 207, 226–228
Amiodarone, thyroid disorders from, 350, 401, 408
Angiography, adrenal evaluations by, 33, 35
ophthalmologic, in diabetic patients, 814–815, 818
Angioplasty, for myocardial infarction, in diabetic patients, 834–835
Angiotensin-converting enzyme (ACE) inhibitors, for myocardial infarction, in diabetic patients, 837–838
Animal models, of autoimmune thyroid disease, sodium-iodide symporter in, 390, 393–395
thyroid-stimulating hormone receptor in, 282–283, 290–291, 440
thyroiditis, 359–361
Anion gap, with diabetic ketoacidosis, calculation of, 692
pathogenesis of, 664–665, 688–689
Antacids, phosphate-binding, for tumor calcinosis, 605
Anti-TSH receptor antibodies (TSHR-Ab), as autoimmune disease marker, 259, 267, 339–340, 392
competitive assay, 340–341
functional assay, 340–341
in autoimmune hypothyroidism, assay applications for, 349–350
prevalence of, 348
in autoimmune thyroiditis, 348
in clinical practice, **339–355**
in Graves' disease, as aid for treatment choice, 342–343
as diagnostic marker, 341–342, 381–382
as severity marker, 342
children and, 347
extrathyroidal manifestations and, 281–282, 347–348
genetics of, 255, 259–261
mouse models of, 282–283, 290–291, 440
new insights into, 267, 280–284, 289
pregnancy and, 345–347
thyroid cancer and, 348
treatment applications of, 343–345
in Hashimoto's disease, 358
in thyroid disease. See also *specific disease.*
as autoimmune marker, 255, 259–261, 267–286, 348, 389
miscellaneous disorders of, 348–351
treatment applications of, 343–345
maternal-fetal assays, 347
Antibody probes, for thyroid-stimulating hormone receptor, 275–276, 280
Anticoagulant therapies, for hyperglycemic disorders, 699–700, 767
Antiemetics, for type 1 diabetes sick-days, 716, 718, 720
Antihyperglycemic agents. See *Insulin; Oral hypoglycemic agents.*
Antihypertensive agents, diabetic patients and, 737, 777
Antipyretics, for type 1 diabetes sick-days, 717, 719
Apo–1. See *Fas-FasL system.*
Apo2L. See *Tumor necrosis factor-related, apoptosis-inducing ligand.*
Apoptosis, importance of, 375–376
in thyroid, 379–380
with autoimmune disease, 380–383
pathways for, 376–377
physiology of, 375
regulation of, 377–378
Arthropathies, with hyperparathyroidism, 461, 467
Aspiration, of gastric content, by diabetic children, 675
Aspirin, for myocardial infarction, in diabetic patients, 833
Associations, genetic, principles of, 364
ATP-sensitive potassium channel, oral hypoglycemics impact on, 805–806
Autoantibodies, in Graves' disease, ophthalmopathy from, 287–294
passive transfer to fetus, 288, 345–347, 349
thyroid family of, 339
to TSH-receptors. See *Anti-TSH receptor antibodies.*
Autoimmune hypothyroidism, atypical patterns, 349–350
diagnostic markers of, 348–349
screening for, 409, 418
spontaneous remission from, 349
Autoimmune thyroid disease (ATD), apoptosis in, genetic pathways of, 375–376, 379–383

new understanding of, **375–388**
chronic inflammatory. See *Hashimoto's disease.*
criteria for, 287–288
growing an interest in, **431–441**
hyperthyroid. See *Graves' disease.*
interview with Robert Volpé, **431–441**
pathogenic antibody markers of, 339–340
population screening for, **239–253**
benefit controversy, 240, 247–249
conditional criteria, 241–245
cost-benefit analysis of, 240, 247–249
needs testing for, 241–249
principles of, 239–241
program criteria, 247–249
recommendations for, 249–250, 409, 418, 427
test criteria, 245–246
treatment criteria, 246–247, 249
prevalence of, 339
sodium-iodide symporter role in, 391–395
thyroid-stimulating hormone receptors in. See *Anti-TSH receptor antibodies.*
thyroiditis as, 348–350
Autoimmune thyroiditis. See also *Hashimoto's disease.*
experimental, 359–360
spontaneous, 360–361
Autopsy examinations, adrenal incidentalomas in, 146, 161–162, 164, 176
thyroid incidentalomas in, 188–189, 192, 194
Autosomal dominant hypophosphatemic rickets (ADHR), 597–598
Availability heuristics, 93–94

B lymphocytes, in autoimmune thyroid disease, 287–288, 381
in Graves' ophthalmopathy, 287, 290–292, 309
Bacterial infections, ocular, in diabetic patients, 821–822
Bayes' Theorem, of probability, 98–99
Bayesian approach, for diagnoses, adrenal case example, 99–101
of incidentalomas, 91–93, 103
pituitary case example, 102–103
steps of, 93–99
pretest probability estimation, 93–95
probability updating, 98–99
test interpretation and performance, 96–98
threshold probability setting, 95–96
thyroid case example, 101–102
Beckwith-Wiedemann syndrome, clinical features of, 2
Benign familial hypocalciuric hypercalcemia (BFHH), 482–483, 505
Beta-blockers, for diabetic patients, blood sugar impact of, 691, 701, 738, 749
hyperglycemia from, 794
hypoglycemia from, 796–797
with myocardial infarction, 836–837
Biases, in diagnosing, 93–96, 98
Bicarbonate levels, with diabetic ketoacidosis, cerebral edema and, 677–678
in children, 662, 664
replacement guidelines for, 671, 674, 696–697, 699
Biguanides, nonhypoglycemic reactions with, 807
Biochemical markers, of bone remodeling, 453–454
of primary hyperparathyroidism, 451–455
Biochemical screening, for MEN–1 syndrome, 556–559
Biopsies. See *Fine-needle aspiration biopsy.*
Bisphosphonates, for hyperparathyroidism, 515, 525–526, 530
parathyroid hormone–related protein levels and, 632
Blood-brain barrier, glucose transport across, insulin-dependence of, 726–727
modulation impact of, 730–734
Blood glucose levels. See also *Hyperglycemia; Hypoglycemia.*
diabetes monitoring recommendations for, 700
during hospitalization, 755–756
during pregnancy, 778
with ketoacidosis, 658, 666, 674–675
with type 1 diabetes sick-days, 717
diabetic retinopathy risks, with rapid normalization of, 773–774
fetal effects of, 773, 781
with diabetic ketoacidosis, 659–660, 664, 689
with hyperglycemic hyperosmolar nonketotic syndrome, 690, 693–694
Blood glucose tests, for insulinomas, 546
Bone cancer, metastatic, hypercalcemia mechanisms with, 629–631
Bone disease, hypophosphatemic, 598
Bone formation, biochemical markers of, 453–454
parathyroid hormone–related protein and, 634–635, 637, 639
Bone histomorphometry, for primary hyperparathyroidism, 471
Bone mineral density (BMD), hyperparathyroidism and, familial, 506
primary, 456–458

Bone mineral density (BMD) *(Continued)*
surgery per, in asymptomatic patients, 469–471, 490
menopause and, 456–459
hormone replacement therapy for, 526–530
parathyroid hormone effects on, differential assessment of, 456–458, 470–471
parathyroidectomy impact on, 455, 459–460, 491, 496
vitamin D impact on, 591–592, 614–615, 617
Bone mineralization, nutrients for, 591–592, 614
Bone remodeling, extracellular calcium and, 505
with hyperparathyroidism, biochemical markers of, 453–454
bisphosphonates impact on, 525–526, 530
differential, 457–458, 460
hormone replacement therapy and, 526–530
surgery impact on, 454–544
with pseudohypoparathyroidism, 578–579, 584
Bone resorption, biochemical markers of, 453–454
Bowel preparation, for adrenalectomy, 59–60
Brain, glucose metabolism by, 711, 726–727
hypoglycemia and, 726–727
modulation impact of, 730–733
glucose regulation by, 727
Breast cancer, hypercalcemia mechanisms with, 630–631
British endocrinologists, on pituitary incidentaloma, management survey, 223–229
test-ordering practices, 207, 226–27, 228

Calcimimetics, for primary hyperparathyroidism, 530–535
Calcitonin, in primary hyperparathyroidism treatment, 531–532, 536
Calcitriol, indications for, 603, 621
serum, hypophosphatemic rickets and, 592–593, 597, 599
tumor calcinosis and, 604
tumor-induced osteomalacia and, 601–602
Calcium, serum, vitamin D deficiency and, 614, 618–623
with hyperparathyroidism, as elevated. See *Hypercalcemia.*
as normal, 453, 484
differential diagnosis of, 483–484
surgery impact on, 454
urinary, parathyroid hormone–related protein and, 632
with hyperparathyroidism. See *Hypercalciuria.*
with vitamin D therapy, 617
Calcium homeostasis, abnormal. See *Pseudohypoparathyroidism.*
extracellular, mechanisms of, 503–505, 513–514
parathyroid hormone regulation of, 570–571
resistance disorders of, **503–522**
treatment of, 530–535
intracellular, parathyroid hormone regulation of, 570–571
Calcium sensing disorders, **503–522**
acquired, 518–519
inherited, 505–518
medical treatment of, 530–535
Calcium supplements, for familial hyperparathyroidism, 507
for vitamin D deficiency, 615–616, 621–623
Calcium to creatinine clearance ratios, familial hyperparathyroidism and, 506–508
Calcium tolerance test, oral, 524–525
cAMP excretion pathway, with hereditary rickets, 599
with hyperparathyroidism, 524, 526, 629
with pseudohypoparathyroidism, 570–571, 574–575, 584
cAMP production pathway, adrenal incidentalomas and, 4, 6
in Graves' ophthalmopathy, 289–290
sodium-iodide symporter in, 390, 392
thyroid-stimulating hormone receptor and, 269, 273, 275
diagnostic applications of, 340–341, 381–382
with primary hyperparathyroidism treatments, 524, 526
Cancer. See also *specific anatomy or type.*
hypercalcemia with, bioassays for, 630
parathyroid hormone–related protein and, 629–632
vitamin D deficiency and, 615
Candidate genes, in Graves' disease, 261–263
Carbohydrate load, diabetic ketoacidosis and, 659–660
Carbohydrate metabolism, disturbances of, with diabetic ketoacidosis, 659–660
Carbohydrates, for diabetes management. See *Glucose administration.*
Carcinoid tumors, in MEN–1 syndrome, 542–544, 548–549

Cardiovascular disease, mild hypothyroidism with, as treatment indication, 404–405
parathyroid hormone–related protein and, 639–640
with hyperparathyroidism, 460–461, 491, 497
Cardiovascular function, in diabetic patients. See also *Myocardial infarction.*
sulfonylureas' impact on, 806
with diabetic ketoacidosis, 665–666
mild hypothyroidism and, treatment indications with, 406
Carney syndrome, clinical features of, 2–3, 9
Cartilage formation, parathyroid hormone–related protein and, 634–637, 639
Caspases, in apoptotic pathways, 376–378
Catecholamines, from neuroblastomas, 37
hypoglycemia unawareness and, 733
in diabetic ketoacidosis, 659, 687
with pheochromocytomas, 32, 100, 116, 129, 149
CD28 gene, in Graves' disease, 256, 259–260
Central nervous system, glucose utilization by, 711, 726–727
modulation impact of, 730–733
Central retinal artery occlusions, 818–819
Central retinal vein occlusions, 819
Cerebral edema, with diabetic ketoacidosis, 699
in children, incidence of, 675–676, 679
pathophysiology of, 661, 664, 675–679
treatment of, 679–680
Cerebral hypoxia, with diabetic ketoacidosis, 678
Chemotherapy, for pancreatic tumors, 546–547
Children, diabetes mellitus, onset in, 657
diabetic ketoacidosis in, **657–682**
acid-base disturbances with, 661
cerebral edema from, 677–678
compensatory mechanisms for, 661–664
management guidelines for, 668–671, 674
causes of, 657–658, 663
cerebral edema with, incidence of, 675–676, 679
pathophysiology of, 661, 664, 675–679
treatment of, 679–680
complications of, 675–680
epidemiology of, 657–658
hospitalization for, 657–658, 662, 665
ketone body monitoring for, 711, 713–714
management of, 665–680
bicarbonate, 671
electrolytes, 668–670
fluids, 668–670, 678–679
general concepts for, 665–666
glucose, 670–671
initial, 665–666
insulin, 666–668
supportive, 673–675
monitoring recommendations, 658, 666, 673–675
pathophysiology of, 658–661
precipitating factors of, 657–658, 663
prevention of, 658
recurrent episodes of, 658
severity parameters for, 661–663
signs and symptoms of, 657–658, 663–665
Graves' disease in, 329–330, 347, 440
postpartum thyroid disease in, growth and development impact of, 405, 407, 423
Chloride to phosphate ratio, with hyperparathyroidism, 484
Chlorpropamide, for diabetic patients, 737, 765
Cholesterol emboli, in diabetic patients, 818
Cholesterol levels, in diabetic patients, 832
thyroid disease impact on, 246–247
as treatment indication, 404–405, 408
Chondrodysplasia, parathyroid hormone–related protein and, 635–637
Chromosome mutations. See also *Gene mutations.*
11p15, 5–9, 17–18
11q13, 551, 555–556
17p13, 8, 10, 17–18
in adrenal neoplasms, 5–10, 16–19
in Graves' disease, 256–263
2q33, 260, 263
6p21, 257, 263
14q31, 261, 263
20q11.2, 261, 263
Xq21.33–22, 262–263
in Hashimoto's disease, 362–363, 367–368
21, 363, 367
X, 362–363
in pseudohypoparathyroidism, 577–579, 581–583
20q, 579, 581–582, 585
of extracellular calcium-sensing receptor, 508–513, 515–518
3, 508, 515
19, 508
q21–24, 508
of hypophosphatemia, 597, 600
of MEN syndromes, 542, 551–556

Cigarette smoking, Graves' ophthalmopathy and, 300, 303, 310, 316
mild hypothyroidism and, 402
Cimetidine, for gastrinomas, 546
Cisapride, for diabetic patients, cytochrome P450 enzyme interactions with, 799
Clodronate, for primary hyperparathyroidism, 525, 535–536
Clonal analysis. See *Genetic cloning.*
Cognitive biases, in diagnosing, 93–96
Cognitive function, thyroid disease impact on, 405, 407, 423
Collagenomas, in MEN–1 syndrome, 542–544, 549
Coma. See also *Hyperglycemic hyperosmolar nonketotic syndrome.*
with diabetic disorders, 661, 666, 675
Computed tomography (CT) scans, for fine-needle aspiration biopsy (CT-FNA), 35, 174–177
for parathyroidectomy localization, 486
Hounsfield scale for, 30, 32, 118, 121, 169–170
image resolution determinants, 160, 169
incidentaloma discovery by, 1, 127, 141, 146, 160
of adrenal cancer, 20, 117–118, 151
of adrenal incidentalomas, 27–32, 35–41, 58, 147, 160–163, 169–174
serial follow-up recommendations, 59, 121, 136–137, 153–154, 180
of adrenal masses, 136–137, 151
of pituitary incidentalomas, 205–206, 212
of thyroid incidentalomas, 189–190, 196
Computer software, for meta-analyses, 89–90
Congenital anomalies, diabetic women and, first-trimester consideration of, 772–773, 782
Conn's syndrome, in MEN–1 syndrome, 549
Continuous subcutaneous insulin infusion therapy, diabetic ketoacidosis from, 658, 690–691
infection healing and, 753–754
ketone body monitoring and, 714
regulation challenges of, 725, 779
Coronary artery bypass grafting (CABG), in diabetic patients, for myocardial infarction, 834–835
glucose control with, 747, 750, 752
Corticosteroids, for diabetic patients, during hospitalization, 749, 756, 763–764
hyperglycemia from, 792
Corticotropin-releasing hormone (CRH) test, for adrenal pathology, 48, 109–111, 148
Cortisol levels, diurnal rhythm of, 4, 48–50, 111–112, 128, 148, 167, 211
in diabetic patients, gestational diabetes and, 778
glucose homeostasis and, 728–729, 733, 745
with diabetic ketoacidosis, 659, 686, 707
in subclinical Cushing's syndrome, 45–52, 109–113
suppressibility tests. See *Dexamethasone suppression test.*
with adrenal cancer, 17–18, 20
with adrenal incidentalomas, 4–6, 109–113, 128–129, 146, 148, 167
with pituitary incidentalomas, 210–212
Cost-effectiveness analysis, methods used for, 89–90
of adrenal incidentaloma management, 70–83, 120
quality-adjusted life-years and, 89–90
Cost-effectiveness ratio, incremental, 90
Cosyntropin stimulation tests, with adrenal incidentalomas, 168–169, 174
Counterregulatory hormones, hyperglycemic disorders from, diabetic ketoacidosis as, 659–660, 683, 686–687
hospital management of, 745–746
hyperglycemic hyperosmolar nonketotic syndrome as, 683, 687
with type 1 diabetes, 707–708, 710
hypoglycemia correction by, 726–727, 733734
Cranial nerve palsies, oculomotor, in diabetic patients, 819–821
Creatinine clearance, hyperparathyroidism and, 472, 484, 506–508
Cryopreservation, with parathyroidectomy, 494–495
Cryotherapy, of adrenal glands, 65
CTLA–4 gene, in Graves' disease, 257–263
in Hashimoto's disease, 365–366, 368
Cushing's syndrome (disease), adrenal cancer with, 18, 20
adrenaloma vs., 146, 148, 164–167, 173
adrenocorticotropic hormone and, 44–45, 47–48, 50, 109–112
classical (overt), features of, 43, 49, 113, 120, 148, 208
prevalence of, 43–44, 53
cortisol levels and, 45–52, 109–113
definitions of, 43
dexamethasone suppression test for, 45, 47–50, 52, 110–111
diagnostic difficulties of, 210–213
differential diagnosis of, 146, 148, 164–167, 173
evolution of, 48–49
genetic pathophysiology of, 4–6

glucocorticoid production with, 43, 47–51, 53
glucose tolerance disturbances with, 45, 50–51
in MEN–1 syndrome, 545, 548–549
preclinical, 43, 164–167
prevalence of, 43–44, 109, 206, 216
subclinical, **43–56**
biochemical screening for, 47–51, 109–111, 146–147
epidemiology of, 44–45
features of, 43, 45–47, 109, 111, 148, 164–167, 208
prevalence of, 44, 109
scintigraphy screening for, 51–52, 148
therapeutic considerations, 52–54
surgical management of, case examples of, 45, 52–53
glucocorticoid replacement with, 53
indications for, 52, 54, 120, 152–153
preoperative considerations, 60
Cyclosporin A, for Graves' ophthalmopathy, 297, 314–315
thyroid cancer and, 333
Cytochrome P450 isoenzyme system, drug interactions with, in diabetic patients, 799–800
metabolic role of, 798–799
Cytokines, adrenal cancer and, 16–17
in autoimmune thyroid disease, Graves', 255–256, 260, 292–293, 393
sodium-iodide symporter and, 392–393
thyroid apoptosis and, 380, 382–383
Cytotoxic T-lymphocyte (CTL)-mediated cell killing, 376–378
in thyroid disease, 380–383

Data aggregation, methods used for, 89–90
de Quervain's thyroiditis, 351, 434
Decoy receptors (DcRs), as apoptosis inhibitors, 378
Dehydration, with diabetic ketoacidosis, fluid therapy for, 668–670
pathophysiology of, 659–661, 688
signs and symptoms of, 663–664
with hyperglycemic hyperosmolar nonketotic syndrome, 688–689
with type 1 diabetes sick-days, prevention of, 716–717
Dehydroepiandrosterone sulfate (DHEA-S), adrenal incidentalomas and, 48, 112, 132, 167
Dent's disease, 593
Depression, postpartum, with thyroiditis, 423–424
Developmental changes, with pseudohypoparathyroidism, 569, 571
Dexamethasone suppression test, overnight, for adrenal incidentalomas, 17, 110, 113, 127, 146, 148, 164, 167
for pituitary incidentalomas, 210–212
for subclinical Cushing's syndrome, 45, 47–50, 52, 110–111
Diabetes mellitus, complications of. See also *specific complication.*
as life-threatening, 683, 699–700
long-term prevention of, 725–726
vascular. See *Myocardial infarction; Ophthalmologic emergencies; Stroke.*
drug interactions and, dangerous and common, **789–802**
of agents used to treat, **803–811**
glucose controls with, as management. See *Glycemic control.*
counterregulation of, 727–730
physiologic mechanisms, 725–726
hospital management of, **745–770**
insulin-dependent. See *Type 1 diabetes mellitus.*
myocardial infarction with. See *Myocardial infarction.*
non–insulin-dependent. See *Type 2 diabetes mellitus.*
pregnancy and. See *Gestational diabetes; Pregnancy.*
sick-day management of, **707–723**
steroid-induced, 754, 756
therapy noncompliance with, hyperglycemic disorders from, 691–692, 700, 709
types of, 657, 708, 711, 718. See also *specific type.*
during hospitalization, 754–757
unrecognized, with hospitalization, 748–749
Diabetic ketoacidosis (DKA), **683–705**
cerebral edema from, 676–680
clinical evaluation of, 692–693
with type 1 diabetes, 710–714
clinical presentation of, 661–663, 689
definition of, 661–663
epidemiology of, 657–658, 684, 708–709
in children, **657–682**. See also *Children.*
in pregnant women, 659, 776–777
management of, 694
acidosis correction, 696–697
electrolyte replacement, 697–698
fluid replacement, 694–695
hyperglycemia correction, 696–697
in children, 665–680
inpatient. See *Hospital management.*
outpatient, 709–710
precipitating causes, 698–700, 719–720
realistic diabetes regimen as, 700
sick-day, with type 1 diabetes, **707–723**
metabolic disturbances with, 657–659, 664–665

Diabetic ketoacidosis (DKA) *(Continued)*
mortality of, 684
pathophysiology of, hyperglycemia as, 686–687, 689
in children, 658–661
insulin deficiency as, 685–686
ketosis and acidosis, 687–688
volume and electrolyte depletion, 688
precipitating factors of, 690–691
in children, 657–658, 663
management of, 698–700, 719–720
with type 1 diabetes, 707–710, 719
prevention of, 658, 700–701
self-management of, on type 1 diabetes sick-days, 709–710, 717
rules for, 715–720
Diabetic nephropathy, during pregnancy, 777
Diabetic retinopathy, clinical findings with, 814–815
hemorrhagic, 816–817
incidence of, 813–814
intensive glycemic control impact on, 773–774, 814
management of, medical strategies, 817
photocoagulation laser for, 815–816
vitrectomy indications for, 817
proliferative, 814–818
screening guidelines for, 817–818
with pregnancy, 774–776
Diabetic vitrectomy, for retinopathy, 817
Diazoxide, for hypoglycemia, 736–737
for pancreatic tumors, 546
Dietary intake, diabetes mellitus and, during hospitalization, 746–747, 755–757
hypoglycemia prevention with, 735–736
pregnant women and, 776, 780–781
Differential diagnoses, clinical approaches to, 92
1,25-Dihydroxyvitamin D, hyperparathyroidism and, 453, 455, 474
extracellular calcium-sensing receptor and, 504–505
treatment impact on, 524, 534
hypophosphatemia and, 594, 603
pseudohypoparathyroidism and, 571
synthesis activation of, 634
vitamin D deficiency and, causes of, 611–612, 617–620
for monitoring, 615–616, 622
2,3-Diphosphoglycerate levels, in red blood cells, with diabetic ketoacidosis, 661, 670, 678
Diuretics, for diabetic patients, hyperglycemia from, 793–794
for hypophosphatemic rickets, 603
for primary hyperparathyroidism, 515, 536
parathyroid hormone–related protein and, 632
DNA cloning. See *Genetic cloning.*
DNA linkage analysis, for MEN–1 screening, 557–558
of familial hyperparathyroidism, 481, 508
of phosphate metabolism disorders, 600, 604
of pseudohypoparathyroidism, 579, 581
Down's syndrome. See *Trisomy 21.*
Drug interactions, in diabetes mellitus patients, alpha-glucosidase inhibitors, 807–808
background on, 789–790
biguanides, 807
common and dangerous, **789–802**
cytochrome P450 isoenzyme system, 798–800
hyperglycemia causes, 792–795
hypoglycemia causes, 796–798, 803
insulin, 803–805
meglitinides, 806–807
of agents used to treat, **803–811**
pharmacodynamics of, 791–792
pharmacokinetics of, 791–792
sulfonylureas, 805–806
thiazolidinediones, 808–809
Drugs, diabetic ketoacidosis from, 690–691, 701
glycemic control and, 691, 701, 738, 749, 761
thyroid disorders from, 350, 401–402, 408

Electrocardiogram changes, with potassium imbalance, 665
Electrolyte disturbances, with diabetic ketoacidosis, 659–661, 664–665
replacement therapy for, 697–699
in children, 668–670, 674
Endocrine function tests, for MEN–1 screening, 559
Endocrine syndrome, post adrenalectomy, 47, 53, 64, 113
with adrenal cancer, 20–21
Endocrine tumors, hypercalcemia mechanisms with, 631
multiple. See *Multiple endocrine neoplasia.*
Endogenous insulin patterns, for glucose counterregulation, 727–729
insulin therapy vs., 725–726
Endopeptidase inhibitor, for hypophosphatemic rickets, 603
Endophthalmitis, in diabetic patients, 821–822
Enteral nutrition, glucose control with, 762
Enzyme pathways, mutations of, in adrenal neoplasms, 112–113

Enzyme tests, for ketone bodies, in diabetic ketoacidosis, 711–712
Epinephrine, glucose homeostasis and, 707, 726–729, 745
  hypoglycemia unawareness and, 733–734
Estrogen, bone density and, 456–458, 471
  for primary hyperparathyroidism, 526–530
Estrogen-containing compounds, for diabetic patients, hyperglycemia from, 795
Ethanol intake, in diabetic patients, 662, 738, 796
Euglycemic diabetic ketoacidosis, 689
Euthyroidism, for Graves' ophthalmopathy, relevance of, 303, 306–310
  postpartum, with thyroid antibody positivity, 422–423
Evidence-based medicine, adrenal incidentaloma guidelines, 82–83
  concept of, 91–92
  for Graves' ophthalmopathy, **297–319**
  for hospital management, of diabetes, 749–754
Exercise, diabetes and, 735, 780
Exophthalmos. See *Graves' ophthalmopathy.*
Experimental autoimmune thyroiditis (EAT), 359–360
Exploratory surgery, for parathyroidectomy localization, 484–485, 488–489
Extracellular calcium (Ca^{2+}_o), disorders with resistance to, **503–522**
  acquired, 518–519
  inherited, 505–518
  medical treatment of, 530–535
  homeostasis mechanisms of, 503–505, 513–514, 570–571
  parathyroid tumor sensitivity to, 526
Extracellular calcium-sensing receptor (CaR), G protein-coupled, acquired disorders of, 518–519
  as key homeostasis mediator, 503–505, 513–514
  chromosome mutations of, 503–504, 508–513
  genotype-phenotype relationships of, adult, 513–514, 517–518
  neonatal, 515–518
  inherited abnormalities in, 505–518
  medical alteration of, 530–535
Extracellular water, osmotic shifts of, with diabetic ketoacidosis, 660–661, 688
  in children, 676–677

Facial angiofibromas, in MEN–1 syndrome, 542–544, 549
Familial hyperparathyroidism, types of, 467, 480–481
  without other endocrinopathies, 480–482
Familial hypocalciuria hypercalcemia (FHH), **503–522**
  clinical features of, 505–506, 511, 517–518
  diagnosis of, 507
  pathophysiology of, 507–513
Familial isolated acromegaly, 555
Familial syndromes, of primary hyperparathyroidism, 467, 480–482, **503–522**
Fanconi's syndrome, 593
Fas-FasL system, as apoptotic pathway, 376–378
  in thyroid, 379–383
Fat metabolism, disturbances of, with diabetic ketoacidosis, 659
Fatty acids. See *Free fatty acids.*
Feminizing tumors, adrenal-based, 20, 146, 168–169
Fetal surveillance, with gestational diabetes, 773, 781
  for anomalies, 772–773, 782
  macrosomia risks, 781–782
Fibrinolysis. See *Thrombolytic therapy.*
Fine-needle aspiration biopsy (FNA), computed tomography guided (CT-FNA), 35, 174–177
  of adrenal incidentalomas, 59, 152, 174–177
  of adrenal masses, 35, 118–119, 133, 135–136
  of metastatic adrenal cancer, 35, 118–119, 135–136
  of thyroid incidentalomas, 192, 194–197, 201
  risks of, 35, 118–119
  ultrasound guided (US-FNA), 35, 119, 192, 194–197, 201
Fludrocortisone suppression test, for adrenal pathology, 115–116, 129, 149
Fluid overload, with diabetic ketoacidosis, in children, 675–676, 678–679
Fluid replacement therapy, for diabetic ketoacidosis, 694–695
  in children, 659–660, 664–666
    cerebral edema from, 675–676, 678–679
    intravenous guidelines for, 668–669, 679
  vs. for dehydration, 669, 716–717
  for hyperglycemic hyperosmolar nonketotic syndrome, 694–695, 697
  for type 1 diabetes sick-days, 716–718
5-Fluorouracil, for gastrinomas, 546
Fractures, with primary hyperparathyroidism, 458, 473
Free fatty acids, as metabolic stress response, 745–746

Free fatty acids *(Continued)*
in diabetic ketoacidosis, 659, 687, 710
in hyperglycemic hyperosmolar nonketotic syndrome, 688
Funduscopic examination, of diabetic patients, 814–815, 818
Fungal infections, ocular, in diabetic patients, 822–823

G protein, mutations of, adrenal neoplasms and, 4–6, 16
Gastric decompression, for diabetic ketoacidosis, 675
Gastric inhibitory peptide (GIP) receptor, adrenal masses and, 4–6, 9, 44
Gastrinomas, in MEN–1 syndrome, 542, 544–546
Gastrointestinal reactions, with hypoglycemic agents, 805, 807–808
Gene mutations. See also *Chromosome mutations.*
in adrenal neoplasms, 4–10, 16–18, 113, 169
in hypophosphatemia, 594–598, 600–601
in MEN syndromes, 542, 551–556
in pseudohypoparathyroidism, 569–570, 576–579, 581–585
in vitamin D metabolism disorders, 619–620
of extracellular calcium-sensing receptor, 503–505, 508–513
of parathyroid hormone–related protein, 634–637
of sodium-iodide symporter, 390–392
General surgery, glucose control with, 750, 753–754, 759–760
Genetic associations, principles of, 364
Genetic cloning, for calcium sensing analysis, with primary hyperparathyroidism, 503, 517–518, 530
in adrenal cancer research, 3–4, 17
in hypophosphatemia studies, 595–597
in malignancy-associated hypercalcemia, 630
in vitamin D metabolism disorders, 619
Genetic screening, for MEN–1 syndrome, 556–559
Genetic structure, of parathyroid hormone–related protein, 632–633
Genetic studies, in autoimmune thyroid disease, apoptosis pathways, 375–376, 379–383
Graves', 255–263
Hashimoto's, 359–369
sodium-iodide symporter in, 390–392
thyroid-stimulating hormone receptor in, 269, 272–273
of adrenal incidentalomas, 3–4, 8–10, 152
of adrenal neoplasms, 9–10, 16–19, 152, 169
of MEN syndromes, 551–560
of phosphate metabolism disorders, 594–598, 600, 604–605
of pseudohypoparathyroidism, 569–570, 576–579, 581–585
of vitamin D metabolism disorders, 619–620
Genetic syndromes, of adrenal cancer, 16–18
of adrenal incidentalomas, **1–13,** 16
of primary hyperparathyroidism, 480–482, 508
Genomic hybridization, comparative (CGH), of adrenal cancer, 17–19
Gestational diabetes. See also *Pregnancy.*
congenital anomalies with, 772–773, 782
cortisol levels with, 778
fetal surveillance with, 772–773, 781–782
glycemic control with, deleterious effects of, 772–773
during labor and delivery, 782–783
eye emergencies with, 772–776
gestational diabetes and, 778–780
insulin therapy for, 779–780, 782–783
postpartum, 783
growth hormones with, eye emergencies and, 773–774
intrauterine growth retardation with, 773, 781–782
macrosomia with, fetal, 781–782
thyroid disease, 776
Trisomy 21 with, 782
GHRHomas (growth hormone–releasing hormone tumors), in MEN–1 syndrome, 542, 548
Glomerular filtration rate (GFR), diabetic ketoacidosis and, 660, 664, 670
Glucagon, for hypoglycemia, 737–738
in diabetic ketoacidosis, 659, 687, 707
injection techniques for, 737
stress triggers for, 727–728, 745
Glucagonoma, in MEN–1 syndrome, 542, 544, 547
Glucocorticoids, for diabetic patients, during hospitalization, 749, 756, 763–764
for Graves' ophthalmopathy, 313, 315
production of, in Cushing's syndrome, 43, 47–51, 53
with adrenal cancer, 17, 58
Gluconeogenesis. See *Hepatic gluconeogenesis.*
Glucose administration, for diabetic ketoacidosis, in children, 670–671
for hypoglycemia, 735–738
for type 1 diabetes sick-days, 716, 718
for type 2 diabetes hypoglycemia, 736–737

Glucose control. See *Glycemic control.*
Glucose levels, decreased. See *Hypoglycemia.*
elevated. See *Hyperglycemia.*
monitoring of. See *Blood glucose levels; Urinary glucose levels.*
physiologic control mechanisms for, 725–726
counterregulation of, 727–730
Glucose tolerance, disturbances in, with adrenal masses, 113, 129, 148
with Cushing's syndrome, 45, 50–51
Glucose transport protein (GLUT1), for brain glucose utilization, 726–727
modulation impact of, 730–731, 733–734
Glycemic control, for diabetic patients, during hospitalization. See *Hospital management.*
during pregnancy. See *Gestational diabetes; Pregnancy.*
glucocorticoids and, 749, 756, 763–764
goals for, 754
insulin for. See *Insulin therapy.*
medications impacting, 691, 701, 738, 749
monitoring guidelines for, 757–758
myocardial infarction and, 747–751, 766, 835–837
oral. See *Oral hypoglycemic agents.*
Glycopeptide hormones, overexpression of, in pituitary incidentalomas, 205, 207–208, 227
Glycosylation, of hemoglobin. See *Hemoglobin A_{1c}.*
thyroid-stimulating hormone receptor and, 276–277, 279
GNAS1 gene, mutations of, in pseudohypoparathyroidism, 576–579, 581–585
Goiters, 241, 245, 323–324, 330, 351, 401
chronic inflammatory. See *Hashimoto's disease.*
Gonadal dysgenesis, thyroiditis and, 362–363
Gonadotropins, in pituitary incidentalomas, 208, 215
overexpression of, in pituitary incidentalomas, 205, 207–208, 227
Gout, with hyperparathyroidism, 461, 467
Graves' disease, as autoimmune, 221, 241–244, 255–256, 259
apoptosis pathways for, 379–383
sodium-iodide symporter role, 392–395
thyroid-stimulating hormone receptor in. See *Anti-TSH receptor antibodies.*
clinical presentations of, 321, 323–324
diabetes mellitus association with, 256, 278, 298, 438
diagnostic investigations for, 25, 341–343
environmental factors of, 256
epidemiology of, 241–244, 255
genetics of, **255–266**
allele analysis, 257–263
candidate studies, 261–263
CD28 gene, 256, 259–260
chromosome mutations, 256–263
CTLA–4 gene, 257–263
genome-wide studies, 260–263
HLA system in, 256–259, 263
susceptibility loci in, 256–258, 260–263
TSHR gene, 255, 259–261
growing interest in, 433, 436–441
hypothyroidism with, 350
imaging techniques for, 325–326, 332
in children, 329–330, 347, 440
medical treatment of, 326–327, 344–345
ophthalmopathy with, evidence-based treatment approach to, **297–319**
immunology of, **287–296**
passive transfer to fetus, 288, 345–347, 349
pregnancy and, 329–330, 345–347
surgical treatment of, advantages of, **321–337**
indications for, 322–323, 327, 330
procedure comparisons for, 327–329, 345
thyroid storm with, 327, 331–332
treatment of, disagreements on, 221–222, 297–303
history of, 322–323
medical, 326–327
radioactive ablation therapy, 329, 344–345
surgical, 327–329, 345
Graves' ophthalmopathy, anti-TSH receptor antibodies and, 347–348
categories of, treatment per, 312, 316, 330–331
cigarette smoking and, 300, 303, 310, 316
clinical presentations of, 323–324
cost-benefit analysis of therapies for, 298–299
duration patterns, 300–301
euthyroidism for, 303
eye change classifications, 301–303
heterogeneity of patients, 303
natural history patterns, 300–302
sample size, 300
euthyroidism for, achievement method impact, 307–310
relevance of, 303, 306–307
evidence-based approach to treatment of, **297–319**
assessment intervals, 304, 307
controlled studies for, 306–310
euthyroidism for, 303, 306–310
need for, 303–306

Graves' ophthalmopathy *(Continued)*
outcome assessment criteria, 304–306
eye changes with, after treatment, 303, 306–310
classifications of, 301–304
hypothyroidism with, 350
imaging techniques for, 315–316, 331
immunology of, **287–296**
circumstantial evidence for, 291–293
direct evidence for, 288
indirect evidence for, 289–291
immunosuppressive treatment of, controlled studies on, 307–309
disagreements on, 297–299, 302
evidence-based approach to, 310, 312–315
outcome assessment of, 315–316
treatment of, current, 297–298
disagreement in current, 298–303
evidence-based approach to, **297–319**
immunosuppressive, 297–299, 302, 307–310, 312–316
individualized plans, 310–312
per categories, 312, 316
preventive strategies, 331
radiotherapy, 297–299, 307–313
steroids, 297–299, 312–314, 331
supportive, 310
surgical, 297–299, 307–312, 331
Growth factors, adrenal cancer role, 16–17
Growth hormones, deficiency syndrome, screening tests for, 215–216
glucose homeostasis and, 728–729, 733, 745
hypophosphatemic rickets and, 591–592, 603
in diabetic ketoacidosis, 659, 687, 707
in gestational diabetes, eye emergencies and, 773–774
in MEN–1 syndrome, 542, 548
overexpression of, in adrenal incidentalomas, 4–8
in pituitary incidentalomas, 205, 207–208, 210
screening tests for, 227
Gs protein (stimulatory guanyl-nucleotide binding protein), discovery of, 574
a subunit activity, in pseudohypoparathyroidism, 569, 574–576, 579, 584

Hair follicles, parathyroid hormone–related protein and, 638–639
Hartley-Dunhill operation, bilateral subtotal thyroidectomy vs., 328–329
Hashimoto's disease (HT), as autoimmune, 357–358
apoptosis pathways for, 379–383
experimental models, 359–360
genetic susceptibility studies, 363–368
sodium-iodide symporter role, 392–395
spontaneous models, 360–361
diabetes mellitus association with, 360, 364–365, 367
epidemiology of, 358–359
genetics of, **357–374**
allele analysis in, 359–360, 364–365, 367–368
animal models of, 359–361
association studies, 364–367
chromosome mutations, 362–363, 367–368
CTLA–4 gene, 365–366, 368
human studies of, 361–363
inheritance mode of, 361–362
linkage analysis, 364, 367–368
susceptibility studies of, 363–368
hypothyroidism from, 400–401
phenotype of, 357–358
Hematopoietic cell malignancies, hypercalcemia mechanisms with, 631
Hemoglobin A_{1c}, brain glucose utilization and, 729, 733
diabetes diagnosis with, 749
pregnancy impact on, 772, 775–776, 778
Hemorrhagic diabetic retinopathy, 816–817
Hepatic artery embolization, of pancreatic tumors, 546–547
Hepatic function, diabetic pharmacokinetic interactions and, 791–792, 808–809
Hepatic gluconeogenesis, hyperglycemic disorders from, diabetic ketoacidosis as, 659–660, 670, 686, 708
hyperglycemic hyperosmolar nonketotic syndrome as, 687
with type 1 diabetes, 710–711
Hereditary hypophosphatemic rickets, with hypercalciuria (HHRH), 599–601
Herpes zoster ophthalmicus, in diabetic patients, 823–825
Heuristics, in diagnosing, 93–94
Histamine H_2-receptor antagonists, for gastrinomas, 546
HLA system, in Graves' disease, 256–259, 263, 293
in Graves' ophthalmopathy, 288, 292–293
in Hashimoto's disease, 361, 364–368
Hormone hypersecretion, with adrenal cancer, 17–18, 20
with adrenal incidentalomas, case examples of, 128–130
preoperative evaluation of, 58
screening tests for, 108–116, 127–128, 148–151, 164, 166–169
with pituitary incidentalomas, 205–207, 209, 216
screening tests for, 214–217, 227

Hormone replacement therapy, for perimenopausal women, 458, 471, 526–530
Hospital management, of diabetes, **745–770**
for diabetic ketoacidosis, 692, 709–710, 720
in children, 657–658, 662, 665
glucose control during, antihyperglycemic agents for, 754–755
coronary artery bypass surgery and, 747, 750, 752
enteral nutrition and, 762
evidence for, 749–754
food intake for, 755–756
glucocorticoids and, 749, 756, 763–764
goals for, 754
infections and, 747, 750, 753–754
insulin algorithms for, 754, 757–758
transitioning to subcutaneous, 758–759
myocardial infarction and, 747–751
parenteral nutrition and, 762–763
perioperative settings, 750, 753–754, 759–760
pregnancy and, 756–757
rationale for, 747–749
steroid-induced disease and, 754, 756
stroke and, 747, 750–752, 764–765
optimizing, 765–766
incidence of, 747
metabolic stress responses and, 745–747
type 1, 754, 756–757, 759–760, 763
on sick-days, 709–710, 720
type 2, 754–757, 762
unrecognized patients and, 748–749
Hounsfield scale (HU), for computerized tomography, 30, 32, 118, 121, 169–170
Hydration, for primary hyperparathyroidism, 515, 536
b-Hydroxybutyrate, diabetic ketoacidosis and, in pregnancy, 776–777
in type 1 diabetes monitoring, 710–714
sick-day management with, 715, 717–720
quantification methods for, 711–714
1-a-Hydroxylase, hypophosphatemia and, 594
pseudohypoparathyroidism and, 571
vitamin D deficiency and, 618, 621–622
25-Hydroxylase deficiency, in Vitamin D metabolism disorders, 619–620
21-Hydroxylase deficiency (21-OH), with adrenal pathology, 16, 112–114
25-Hydroxyvitamin D, in vitamin D metabolism disorders, 617–620, 622
Hypercalcemia, familial. See *Familial hypocalciuria hypercalcemia.*
from parathyroid tumors, 452–453
malignancy-associated, parathyroid hormone–related protein in, 629–632
with hyperparathyroidism, as parathyroidectomy indication, 472, 474, 490, 496
biochemical markers of, 451–455
clinical features of, 466, 468, 482
nephrolithiasis with, 455
treated vs. untreated, 454–455, 466–468
Hypercalciuria, hereditary hypophosphatemic rickets with, 599–601
hyperparathyroidism and, 455, 468, 472, 490
Hyperglycemia, as metabolic stress response, to acute illness, 691–692, 698–699, 745–747
with type 1 diabetes, 707–708, 719–720
during pregnancy. See *Gestational diabetes; Pregnancy.*
from drug interactions, in diabetic patients, 792–795
hyperglycemic hyperosmolar nonketotic syndrome from, 686–687, 690, 697
inpatient management of. See *Hospital management.*
ketoacidosis from. See *Diabetic ketoacidosis.*
overlooked, with hospitalization, 748
Hyperglycemic hyperosmolar nonketotic syndrome (HHNS), **683–705**
clinical evaluation of, 693–694
clinical presentation of, 690
epidemiology of, 684
management of, 694
acidosis correction, 696–697
electrolyte replacement, 697–698
fluid replacement, 694–695
hyperglycemia correction, 696–697
precipitating causes, 698–700
realistic diabetes regimen as, 700
pathophysiology of, hyperglycemia as, 661, 686–687
insulin deficiency as, 685–686
ketosis and acidosis, 687–688
volume and electrolyte depletion, 688–689
precipitating factors of, 691–692
management of, 698–700
prevention of, 700–701
Hyperparathyroidism, acute, 535–536
primary. See *Primary hyperparathyroidism.*
secondary, from hyperplasia, 519, 523, 526
medical treatment of, 534–535
uremic, extracellular calcium-sensing receptor resistance with, 518–519
Hyperphosphatemia, from tumor calcinosis, 592, 603–605
parathyroid hormone–resistant. See *Pseudohypoparathyroidism.*

Hyperphosphatemia *(Continued)*
renal mechanisms of, 592
Hypersensitivity reactions, local, to insulin injections, 804–805
Hypertension. See also *Stroke.*
adrenal surgery and, 57, 60
adrenal testing for, 100, 113, 115, 128–129, 149
in diabetic patients, 832
pregnancy-induced, 777
with hyperparathyroidism, 461, 467
Hyperthyroidism. See also *Graves' disease.*
epidemiology of, 241–244, 249
subclinical, 242, 247
treatment of, 247
Hyperventilation, for cerebral edema, with diabetic ketoacidosis, 679
Hypocalcemia, parathyroid hormone–resistant. See *Pseudohypoparathyroidism.*
vitamin D deficiency and, 614, 617–620
treatment of, 620–623
Hypocalciuria, familial. See *Familial hypocalciuria hypercalcemia.*
hyperparathyroidism and, 482–483, 505
Hypoglycemia, **725–743**
brain regulation of, 711, 726–727
modulation impact of, 730–733
classic symptoms of, 726
endogenous vs. exogenous regulation of, 725–726
as counterregulation, 727–730
fetal effects of, 773
insulin-induced, 729, 733–736
severe, factors influencing, 737–738
physiologic counterregulation mechanisms for, 727–730
brain modulation of, 730–733
predicting, 734–735
prevention of, 734–735
with hospitalization, 747–748
with type 1 diabetes sick-days, 716–717
treatment of, insulin regimens, 734–735
oral regimens, 735–736
with type 2 diabetes, 736–737
unawareness of, 726, 733–734, 738
with diabetes mellitus, from drug interactions, 796–798, 803
type 1, 716–717, 725–726, 728–729, 731, 737
type 2, 725–726, 728–729, 736–737
with diabetic ketoacidosis, 699
in children, 674–675
Hypoglycemia unawareness, physiologic mechanisms of, 726, 733, 738
reversal of, 733–734
Hypoglycemic agents. See *Insulin; Oral hypoglycemic agents.*
Hypoparathyroidism. See *Pseudohypoparathyroidism.*
Hypophosphatemic disorders, autosomal dominant rickets, 597–598
bone disease, 598
bone mineralization and, 591–592
calcium and, 592–593
hereditary rickets with hypercalciuria, 599–601
initial evaluation of, 593
renal function and, 591–593
treatment of, 602–603
tumor-induced osteomalacia, 601–602
X-linked rickets, 593–597
Hypothalamo-pituitary-adrenal (HPA) axis, abnormalities of, with adrenal incidentalomas, 108–112, 120
Hypothyroidism, anti-TSH receptor antibodies in, as marker of, 348
assay applications for, 349–350
autoimmune, 348–350
diabetes mellitus association with, 407
epidemiology of, 241–244
Graves' disease with, 350
neonatal, transient transplacental, 288, 329, 345–347, 349
permanent postpartum, 422
post-thyroidectomy, 328
subclinical, 242, 246, 328, 400. See also *Mild hypothyroidism.*
treatment of, 246–247
preventive, 403–404
with gestational diabetes, 776

Iatrogenic thyroid disorders, 350
Idiogenic osmols, 676, 699
IgG levels, in postpartum thyroiditis, 425
thyroid disease and, 255, 290, 293, 394
Imaging phenotype, for adrenal incidentalomas, 117–118, 169–174
Imaging techniques. See also *specific anatomy or technique.*
computerized, evolution of, 160
phenotypes from, 169
for Graves' disease, 325–326, 332
for Graves' ophthalmopathy, predictive values of, 315–316, 331
for postpartum thyroiditis, 424–425
incidentaloma discovery by, 1, 27, 57, 69, 127, 136–138, 141, 146, 160
Immune function, in diabetic patients, 728, 747
Immune response, to iodide transporter, **389–398**
Immunochemiluminometric (ICMA) assays, hyperparathyroidism diagnosis with, 452–453, 468, 489
in malignancy-associated hypercalcemia, 630
Immunoglobulins, intravenous, for Graves' ophthalmopathy, 297–298, 314–315

Immunology, of Graves' ophthalmopathy, **287–296**
of thyroid-stimulating hormone receptors, 255, 259–261, 267, 280–284
Immunomodulatory proteins, in Graves' disease, 256–259, 263, 293
Immunoradiometric (IRMA) assays, hyperparathyroidism diagnosis with, 452–453, 468, 489
in malignancy-associated hypercalcemia, 630
Incidentalomas, adrenal. See *Adrenal incidentalomas.*
diagnostic dilemma of, **91–105**
adrenal case example, 99–101
Bayesian approach to, 91–99
pituitary case example, 102–103
thyroid case example, 101–102
discovery through imaging techniques, algorithmic management of, 40, 69–70, 127, 136–138
prevalence of, 1, 27, 41, 57, 69, 141, 146, 160
pituitary. See *Pituitary incidentalomas.*
thyroid. See *Thyroid incidentalomas.*
Index tests, interpretation of, 96–98
Infections, in diabetic patients, diabetic ketoacidosis from, in children, 661, 663, 666, 675
pathophysiology of, 690, 698–699
with type 1 diabetes, 708, 710
glycemic control during hospitalizations for, 747, 750, 753–754
hyperglycemic hyperosmolar nonketotic syndrome and, 692, 699
ocular, 821–825
Inheritance patterns, of Albright's hereditary osteodystrophy, 577–578, 584
of phosphate metabolism disorders, 594–601, 604
of pseudohypoparathyroidism, 577–578, 581–584
of vitamin D metabolism disorders, 617–620
Inhibin, adrenal cancer role, 17
Inpatient management, of diabetes. See *Hospital management.*
Insulin allergy, 803–805
Insulin deficiency, in diabetic ketoacidosis, in children, 658–660, 666
pathogenesis of, 683, 685–686, 711
in hyperglycemic hyperosmolar nonketotic syndrome, 683, 686
in type 1 vs. type 2 diabetes, 657, 708, 711, 718
Insulin edema, 803–804
Insulin-like growth factor (IGF), in gestational diabetes, eye emergencies and, 773–774
overexpression of, in adrenal incidentalomas, 5–8
in pituitary incidentalomas, 210, 227
Insulin pump. See *Continuous subcutaneous insulin infusion therapy.*
Insulin reactions, hypoglycemia from, 729, 733–736, 803
severe, factors affecting, 737–738
nonhypoglycemic, 803–805
Insulin resistance, with hyperglycemic syndromes, 686–687, 689
in type 1 diabetes, 708–710
Insulin therapy, during hospitalization, algorithms for, 757–759
guidelines for, 747, 755–756, 758–759
in special circumstances, 759–767, 835–836
endogenous insulin patterns vs., 725–729
for diabetic ketoacidosis, cerebral edema from, 676–680
glucose administration with, 670–671
guidelines for, 696, 699
in children, 666–668
intravenous guidelines for, 667–668, 696
for diabetic patients, 700, 791
during pregnancy, 779–780, 782–783
noncompliance with, hyperglycemic disorders from, 691–692, 700, 709
with myocardial infarction, 835–836
with type 1 diabetes sick-days, 715–716, 718–719
for gestational diabetes, 779–780
during labor and delivery, 782–783
postpartum, 783
for hyperglycemic hyperosmolar nonketotic syndrome, 697
for hypoglycemia prevention, 734–735
intravenous guidelines for, infection healing and, 753–754
perioperative, 750–754, 759–760
special inpatient circumstances and, 759–767, 835–836
transitioning to subcutaneous, 758–759
with diabetic ketoacidosis, 667–668, 696
perioperative, 750–754, 759–760
reactions to. See *Insulin reactions.*
realistic regimen for, 700
Insulinoma, hypoglycemia regulation and, 730, 734
in MEN–1 syndrome, 542, 544, 546–547
Intelligence quotient (IQ). See *Cognitive function.*
Interferon-g (IFN-g), autoimmune thyroid disease and, 350, 379–380, 382, 392, 401

Interferon-g (IFN-g) *(Continued)*
Graves' ophthalmopathy and, 290, 293
Interleukin–1 receptors, adrenal incidentalomas and, 6
Interleukin–1b (IL-b), in thyroid apoptosis, 293, 379, 382, 392
Intracellular water, osmotic shifts of, with diabetic ketoacidosis, 660–661, 688
in children, 676–677
Intracerebral acidosis, with diabetic ketoacidosis, cerebral edema and, 677–678
Intraoperative localization, for parathyroidectomy, 484–485, 488–489
Intrauterine growth retardation, with gestational diabetes, 773, 781–782
Iodide transporter, immune response to, **389–398**
Iodine, dietary supplements, thyroid disease incidence and, 244–245, 401
preoperative, for Graves' disease, 323, 326
solutions, for thyroid storm, 327, 331–332
Iodine ^{123}I imaging, for Graves' disease, 325–326
Iodine ^{131}I therapy, for Graves' disease, 329, 344–345
for Graves' ophthalmopathy, 297–299, 307–315
Iodo-cholesterol scintigraphy (I-NP59), for adrenal incidentalomas, 33, 119, 135, 148, 176, 178
for Cushing's syndrome, 51
Ischemia, silent, in diabetic patients, 832–833
Ischemic cranial nerve injuries, oculomotor, in diabetic patients, 819–821
Ischemic preconditioning, inhibition of, with sulfonylureas, 806
Islet-cells. See *Pancreatic cells.*
Italian Society of Endocrinology, Adrenal Incidentaloma Study Group of (AI-SIE), 107–108
functional status evaluations, 108–116
malignancy evaluations, 116–120
management recommendations, 120–121

Jansen's disease, parathyroid hormone–related protein and, 637
JunD transcription factor, in MEN–1 syndrome, 556, 560

Ketoacids, with diabetic ketoacidosis, 658–661, 664
in children, 658–661, 664
Ketogenesis, 710–711
Ketone bodies, as metabolic stress response, 746
measurement methods for, blood vs. urine, 711–714, 717
with diabetic ketoacidosis, 664, 693, 697
with type 1 diabetes, 711–714, 717–718
with diabetic ketoacidosis, in children, 658–659, 661, 664
mechanisms of, 658–659, 661, 664, 689, 711
Ketone body ratio, 711
Ketonemia, monitoring methods for, 711–714
nondiabetic, 711
with diabetic ketoacidosis, 661–662, 664
in type 1 diabetes, 711–714
Ketonuria, monitoring methods for, 711–714
with diabetic ketoacidosis, 661–662, 664, 688
in pregnant women, 776
in type 1 diabetes, 710–714
Ketosis, definition of, 710–711
diabetic. See *Diabetic ketoacidosis.*
in hyperglycemic hyperosmolar nonketotic syndrome, 688
monitoring of. See *Ketone bodies.*
nondiabetic, 659, 662, 711
pathogenesis of, with diabetes, 687–688, 709–710
in type 1 diabetes, 710–714, 717–718
physiologic, 711
Kidney stones. See *Nephrolithiasis.*
Klebsiella pneumoniae, in diabetic ocular infections, 822
Knudson's model, for tumor development, 551, 554–555

Lactate acidosis, in diabetic patients, 690, 727, 746, 807
children, 662, 664, 671
Lactation, parathyroid hormone–related protein and, 638
Laser photocoagulation, of diabetic retinopathy, 815–816
Leukemia, hypercalcemia mechanisms with, 631
Levothyroxine, indications for, 344, 408, 422
Li-Fraumeni syndrome, clinical features of, 2, 17, 152
Likelihood ratios, of tests, 96–99
Linkage analysis, principles of, 364
Lipidemia. See *Cholesterol levels.*
Lipoatrophy, from insulin injections, 804

Lipohypertrophy, from insulin injections, 804
Lipolysis. See *Free fatty acids.*
Lipomas, in MEN–1 syndrome, 542–544, 549
Lipoprotein levels. See *Cholesterol levels.*
Literature review, of incidentalomas, applications of, 70, 93, 95
Lithium, thyroid disorders from, 401, 408
Localization studies, for insulinomas, 546–547
  for parathyroidectomy, 484–489, 495
Long-acting thyroid stimulator (LATS), 278, 435–436
Loss of heterozygosity (LOH) analysis, in adrenal cancer, 16–18
  in adrenal incidentalomas, 3–4, 8–10
Luteinizing hormone (LH), adrenal incidentalomas and, 6, 9
  pituitary incidentalomas and, 205, 208, 227

Macroadenomas, pituitary, pathophysiology, 206–207, 209, 213–214
  recommendations for, 215–216
Macrosomia, fetal, with gestational diabetes, 781–782
Macular edema, with diabetic retinopathy, 816
Magnesium, serum, extracellular calcium-sensing receptor mutations and, 504–506, 513, 515
Magnetic resonance (MR) imaging, angiography with, adrenal applications of, 33, 35
  for parathyroidectomy localization, 486, 495
  of adrenal cancer, 20, 117–118, 169–172
  of adrenal incidentalomas, 27, 32–33, 58, 169–172
    serial follow-up recommendations, 59, 121, 136–137, 153–154, 180
  of adrenal masses, 135, 137
  of pituitary incidentalomas, 205–206, 209, 212–213, 215, 229
  of thyroid incidentalomas, 189–190
Mammary tissue, parathyroid hormone–related protein and, 637–638
Mannitol, for cerebral edema, with diabetic ketoacidosis, 679–680
McCune-Albright syndrome, clinical features of, 2–4, 16
Mechanical reperfusion, for myocardial infarction, in diabetic patients, 834–835
Medications. See *Drugs.*
Medullary thyroid carcinoma (MTC), 494, 541–542
Meglitinides, for diabetic patients, during hospitalization, 755, 761
  nonhypoglycemic reactions with, 806–807
Membrane receptors, adrenal neoplasms and, 4–6, 9
Membrane signaling pathways, adrenal incidentalomas and, 4–6
MEN1 gene, functions of, 555–556
  identification of, 551
  mutations of, 551–554
    genetic screening for, 556–559
    in endocrine tumors, 554–555
Menin, functions of, 555–556
Menopause, hyperparathyroidism and, bone density per, 456–459
    hormone replacement therapy and, 458, 471, 526–530
    parathyroidectomy indications per, 471, 473, 475
Menstrual disorders, mild hypothyroidism with, as treatment indication, 406–407
Meta-analyses, methods used for, 89–90
  of adrenal incidentalomas, 70–83
Meta-iodobenzylguanidine scintigraphy (MIBG), of adrenal incidentalomas, 33–34, 119, 129, 135, 149
Metabolic acidosis, with diabetic ketoacidosis, management of, guidelines for, 696–697, 699
    in children, 668–671, 674
    pathogenesis of, 687–688
      in children, 658–663
      respiratory compensation mechanisms for, 661, 664
      severity parameters of, 661–664, 689
  with hyperglycemic hyperosmolar non-ketotic syndrome, 688, 690, 697
Metabolism disturbances, with diabetic ketoacidosis, 659–661
    hospital management of, 745–747
Metanephrines, plasma, with pheochromocytomas, 100–101, 116, 149
Metastatic cancer, in adrenal gland. See *Adrenal cancer.*
  of bone, hypercalcemia mechanisms with, 629–631
Metformin, for diabetic patients, 736, 807
  during hospitalization, 755, 761
Methylnorcholesterol scintigraphy, for Cushing's syndrome, 51–52
MHC system, in genetics, of Graves' disease, 256–259, 263
  of Hashimoto's disease, 359–361, 364–368
Microadenomas, pituitary, pathophysiology of, 205, 207, 212–214
  recommendations for, 214–216
Mild hypothyroidism, causes of, 400–402

Mild hypothyroidism *(Continued)*
diagnosis of, strategy for, 407–408
thyroid-stimulating hormone levels in, 399–400, 402–403
thyroxine levels in, 400, 402–403, 407–408
triiodothyronine levels in, 403, 408
history of, 399–400
prevalence of, 400
screening for, 409, 418
terminology of, 399–400
treatment indications for, cardiac function, 406
hyperlipidemia, 404–405, 408
menstrual disorders, 406–407
miscellaneous, 407
neuromuscular function, 406
neuropsychologic symptoms, 405–406
pregnancy, 406–407
prevention of overt disease, 403–404
somatic symptoms, 405–406
strategy for, 407–408
when to treat, **399–415**
Mineral ion homeostasis, abnormal. See *Pseudohypoparathyroidism; specific imbalance.*
extracellular calcium for, 504–505, 513
parathyroid hormone for, 504, 513, 570–571
vitamin D for, 611, 614
Miscarriages, thyroiditis following, 426–427
Mitotane, for adrenal cancer, 21
Molecular studies. See *Genetic studies.*
Multichannel autoanalyzers, hyperparathyroidism diagnosis with, 451–452, 468
Multiple endocrine neoplasia (MEN), surgical treatment of, 494, 523
type 1 (MEN–1), **541–567**
adrenocortical tumors, 542–544, 549
cancer incidence with, 16
carcinoid tumors, 542–544, 548–549
clinical features of, 543–551
collagenomas, 542–544, 549
facial angiofibromas, 542–544, 549
familial, 543, 555–557
features of, 2–3, 9, 152
genotype-phenotype correlations of, 554–555, 557
lipomas, 542–544, 549
molecular genetics of, 551–556
pancreatic tumors, 542–548
parathyroid tumors, 467, 480–481, 542–545
pituitary tumors, 542–544, 548
screening for, 556–559
sporadic, 554–556
thyroid tumors, 542–544, 551
tumor characteristics of, 541–542
type 2 (MEN–2), characteristics of, 541–542
with primary hyperparathyroidism, 480–481
Multivitamins, for vitamin D deficiency, 615–616, 621
Murine mice models, of X-linked hypophosphatemic rickets, 594–595
Myelolipomas, clinical presentations of, 117, 144–145
radiologic evaluation of, 30–31, 37–38
Myocardial infarction (MI), in diabetic patients, **831–842**
clinical presentation of, 832–833
diabetic ketoacidosis with, 691, 699
epidemiology of, 831–832
management of, angiotensin-converting enzyme inhibitors, 837–838
aspirin, 833
beta-blockers, 836–837
glycemic control, 747–751, 766, 837
intravenous insulin therapy, 835–836
mechanical reperfusion techniques, 834–835
thrombolysis, 816, 831, 833–834
mortality rates of, 831–832, 834, 836
pathophysiology of, 832
stroke with, 766–767
Myxedema, disease interpretations of, 347–348, 358, 399

Neonatal hypothyroidism, transient transplacental, 288, 329, 345–347, 349
Neonatal severe hyperparathyroidism (NSHPT), calcium receptor mutations in, heterozygous, 516–517
homozygous or compound, 515–516
clinical features of, 514, 517–518
medical treatment of, 514–515
pathophysiology of, 480–482, 514
surgical treatment of, 494
Neoplasms. See *specific anatomy or type.*
Nephrolithiasis, with hyperparathyroidism, etiology of, 455, 466, 469
treated vs. untreated, 455–456, 466, 490
Nerve palsies, ocular motor, in diabetic patients, 819–821
Neuroblastomas, 37–39
Neuroendocrine markers, of adrenal cancer, 16–17
Neuroglycopenia, 726–727
Neuromuscular function, mild hypothyroidism and, treatment indications with, 406
Neuromuscular syndrome, with hyperparathyroidism, 460, 496

Neuroprotective therapies, in acute stroke, 767
Neuropsychiatric disorders, with hyperparathyroidism, 460, 467–468
as diagnostic criteria, 468–469
as parathyroidectomy indication, 491, 496–497
Neuropsychologic symptoms, postpartum thyroid disorders and, 407, 422–424
with euthyroidism, postpartum considerations, 422–424
with mild hypothyroidism, as treatment indication, 405
postpartum considerations, 407, 423
Nicotinic acid (niacin), for diabetic patients, hyperglycemia from, 795
Nitroprusside reaction, for ketone body measurement, in diabetic ketoacidosis, 693, 697, 711
problems with, 712–713
Norethindrone, for primary hyperparathyroidism, 530
Nosocomial infections, glycemic control with, 747, 750, 753–754
NPO status, glycemic control with, 746–747, 755
NPS R-568, for primary hyperparathyroidism, 531–534
NPT2 gene, mutations of, in hypophosphatemic rickets, 594, 596, 600
Nuclear medicine imaging, for parathyroidectomy localization, 486–488, 495
intraoperative mapping, 489, 492

Octreotide. See also *Somatostatin analogues.*
for diabetic patients, 737
for pancreatic tumors, 546–547
Octreotide scanning, for tumor-induced osteomalacia, 603
Ocular motor nerve palsies, in diabetic patients, 819–821
Omeprazole, for gastrinomas, 545–546
Oncogenes, adrenal incidentalomas and, 8–9
of adrenal cancer, 16–18
Ophthalmologic emergencies, in diabetic patients, **813–829**
during pregnancy, 773–776
infections, 821–825
retinopathy, 773–776, 813–818
vascular events, 818–821, 833
Ophthalmopathy, Graves'. See *Graves' ophthalmopathy.*
NO SPECS index for, 302
applications of, 304–305
criticism of, 303
Oral hypoglycemic agents, for diabetic patients, 729–730, 736–737
contraindications for, 755, 761
pregnancy as, 756–757, 780
during hospitalization, 754–755
nonhypoglycemic reactions to, 805–810
Orbit, B-cell reactivity of, 287, 290–292
Graves' disease and, adipogenesis in, 289–290, 292
autoantibodies of, 289–293
decompression for ophthalmopathy, 297–299, 307–312
imaging techniques for, 315–316
T-cell reactivity of, 287, 290–293
Organification, in thyroid function, 389, 391
Osmolality. See *Serum osmolality.*
Osmotic diuresis, glucose-induced, in stroke patients, 766
with diabetic ketoacidosis, 659–660, 676, 698
with hyperglycemic hyperosmolar nonketotic syndrome, 688–689
Osteitis fibrosa cystica, with primary hyperparathyroidism, 456–458, 466
treated vs. untreated, 458–460, 470–471, 496–497
Osteolysis, parathyroid hormone–related protein and, 629–631
Osteomalacia, tumor-induced, 592, 596, 601–602
vitamin D deficiency and, 615, 618, 622–623
Outpatient management, of diabetic ketoacidosis, 709–710
Oxygen-hemoglobin dissociation, with diabetic ketoacidosis, 661, 670, 678

PAC/PRA ratio, 115, 168
Painless thyroiditis, 350, 358
Pamidronate, for parathyroid crisis, 535–536
Pancreatic cells, b cells, glucose homeostasis and, 728–729
oral hypoglycemic agents and, 736–737, 806
islet-cells, glucose homeostasis and, 728–729, 746
oral hypoglycemic agents and, 736–737, 806
tumors of, in MEN-1 syndrome, 542, 545–548
Pancreatic tumors, in MEN-1 syndrome, 542–548
Pancreatitis, with hyperparathyroidism, 496–497, 505
Parathyroid adenomas, 466, 480

Parathyroid adenomas *(Continued)*
treatment of, 481, 488, 494, 526
Parathyroid carcinoma, medical approaches to, 466, 523–524, 526, 535
natural history of, 452–453
surgical approaches to, 466, 480–481, 483
Parathyroid crisis, medical treatment of, 535–536
Parathyroid hormone (PTH), assay, for parathyroidectomy localization, 488–489, 492, 495
extracellular calcium-sensing receptor feedback loop for, 504–505
disorders of, acquired, 518–519
adult inherited, 507–508, 513, 517–518
neonatal inherited, 514–518
mineral ion homeostasis and, 504–505, 513, 570–571
overproduction of. See *Primary hyperparathyroidism.*
resistance toward. See *Pseudohypoparathyroidism.*
vitamin D deficiency and, 614, 617, 620–622
Parathyroid hormone–related protein (PTHrP), **629–645**
actions of, 634
bioassays for, 630
genetic expression of, 634–637
genetic structure of, 632–633
hypercalcemia in malignancy and, 629–632
hyperparathyroidism and, 453, 483, 629
peptide processes of, 632–634
physiologic roles of, 634–640
Parathyroid hormone–related protein (PTHrP) receptor, mineral ion homeostasis and, 570–571
pseudohypoparathyroidism and, 577, 579, 583–584
structure and affinity of, 633–634, 637
Parathyroid hyperplasia, 519
medical treatment of, 523, 526, 534–535
Parathyroid poisoning, 524–525
Parathyroid tumors, in MEN–1 syndrome, 542–545
Parathyroidectomy, cryopreservation with, 494–495
for hyperparathyroidism, approaches for, 491–494
benefits of, 494–498
bilateral vs. unilateral, 492–493
bone density impact, 455, 459–460
contraindications for, 507, 518
disease impact of, 451, 454–455, 475–476
for familial syndromes, 494
for persistent or recurrent disease, 495–496
incidence of, 479–480
indications for, 489–491, 545
as controversial, 465, 518
per National Institutes of Health, 469, 471–472, 490
potential guidelines for, 472–475
with asymptomatic patients, 468–472, 490–491
with symptomatic patients, 466–468, 490
localization studies for, 484–489, 495
longitudinal studies on, 475–476, 489–491, 496–498
morbidity and mortality of, 491, 497–498, 523
nephrolithiasis impact, 456
observation vs. operation, 465–478
subtotal vs. total with autotransplantation, 493–494, 518
localization studies for, debate about, 484–485, 495
intraoperative, 484–485, 488–489, 492
invasive, 488–489
noninvasive radiographic, 485–488
Parenteral nutrition. See *Total parenteral nutrition.*
Pentamidine, for diabetic patients, hypoglycemia from, 797–798
Peptic ulcer disease, with hyperparathyroidism, 461, 467, 491, 497
Peptide hormones, from parathyroid hormone–related protein, 632–634
phosphate hemostasis and, 570–571, 591–592
in hypophosphatemic disorders, 595, 598, 603
resistance to, 571–574
Percutaneous transluminal coronary angioplasty (PTCA), for myocardial infarction, in diabetic patients, 834–835
Perioperative management, of blood glucose, in diabetic patients, 750, 753–754, 759–760
Pharmacodynamic interactions, in diabetic patients, 791–792
Pharmacokinetic interactions, in diabetic patients, 791–792
Pheochromocytoma, associated pathologies, 59, 120, 494, 631
differential diagnosis of, 146, 148–149, 166, 168, 170–172, 176
features of, 57, 116, 130, 142–143, 150
imaging techniques for, 32, 34, 58, 117–118
silent, 116, 119
subclinical, screening tests for, 129, 146, 148–150
surgical management of, 60–61, 65, 120, 129, 153, 179

PHEX/Phex gene, normal function of, treatment and, 603
Phosphate, as essential nutrient, 591–592
bone mineralization and, 591–592
for hyperparathyroidism, 515, 524–525, 534
for hypophosphatemic rickets, 603
serum, range of, 591
Phosphate metabolism, disorders of, **591–609**
hyperphosphatemic, 592, 603–605
hypophosphatemic, 592–603
hemostasis mechanisms, abnormal. See *Pseudohypoparathyroidism.*
hormone regulation of, 570–571, 591–592
renal reabsorption as, 591–592
with diabetic ketoacidosis, in children, 661, 670, 678
replacement therapy for, 698
Phosphatonin, hypophosphatemia and, 596
Phosphorus, serum, vitamin D deficiency and, 620
with hyperparathyroidism, 453, 466, 468, 484
Photocoagulation laser treatment, of diabetic retinopathy, 815–816
Pituitary incidentalomas, **205–221**
diagnosis of, Bayesian approach example, 102–103
biochemical tests, 209–212, 227–229
hormonal screening tests for, 214–217, 227
imaging techniques for, 205–206, 209, 212–213, 215, 229
test-ordering practices, 207, 226–229
visual field testing, 208–209, 214–215, 227, 229
differential diagnosis of, 205–207
macroadenomas, 206–207, 209, 213–216
management strategies, accurate diagnosis considerations, 209–212
adverse outcome risks, 207–209
cost considerations, 213–214
current clinical practice, 207
development of optimal, 207–214
in presymptomatic patients, 212–214
research questions for, 229
management survey of, American and British, **223–230**
discussion, 227–229
methods, 224
objectives, 223–224
results, 225–227
microadenomas, 205, 207, 212–216
prevalence of, 205–206
quality-adjusted life-years with, 213–215, 228
secretory vs. non-secretory, 205–207, 209, 216
test sensitivities for, 209–217
Pituitary tumors, in MEN–1 syndrome, 542–544, 548
Plasma aldosterone concentration-to-plasma renin activity (PAC/PRA), 115, 168
Plasma anion gap. See *Anion gap.*
Plasmapheresis, for Graves' ophthalmopathy, 315
Population screening, for thyroid disease, appropriateness criteria for, 239–240
autoimmune, **239–253**
benefits analysis of, 240, 247–249
during pregnancy, 346–347
for mild hypothyroidism, 409, 418
lead-time bias in, 240–241
postpartum recommendations, 427–428
tiers of care in, 240
Positron emission tomography, for adrenal incidentalomas, 33, 120
Postabortion thyroiditis, 426–427
Posterior probability, estimation of, 93–95
Postpartum depression, with thyroiditis, 423–424
Postpartum glycemic control, in diabetic patients, 783
Postpartum thyroiditis (PPT). See also *Pregnancy.*
anti-TSH receptor antibodies in, 347, 418, 420
autoimmune, 288, 350, 358
classical definition of, 418–419
depression and, 423–424
diabetes mellitus association with, 420, 427
diagnosis of, 420–421
etiology of, 425–426
history of, 417–418
hyperthyroid phase, 421
hypothyroid phase, 421–422
incidence of, 420
permanent hypothyroidism from, 422
postabortion, 426–427
prevention of, 427
recognizing, understanding, and treating, **417–430**
screening for, 427–428
surgical treatment of, 328–329
ultrasonographic findings in, 424–425
Posttest probability, calculation of, 98–99
Potassium imbalance, adrenal incidentalomas and, 15, 18, 116, 120
with diabetic ketoacidosis, in children, 660–661, 665, 669–670
replacement therapy for, 697–699
in children, 661, 669–670
PPoma, in MEN–1 syndrome, 542, 547
Pragmatic diagnoses, 92
Pre-pregnancy counseling, for diabetic women, 772

Preclinical Cushing's syndrome (PCS), 164–167
Predictive values, of tests, 96–98
Pregnancy, diabetes during, congenital anomalies with, 772–773, 782
diet intake for, 776, 780–781
exercise role in, 780
fetal surveillance with, 773, 781
glycemic control and, 772–776, 778, 782–783
hemoglobin A_{1c} levels with, 772, 775–776, 778
incidence of, 771
insulin doses for, 779–780, 782–783
medical emergencies with, **771–787**
diabetic ketoacidosis, 659, 776–777
hypertension, 777
in first-trimester, 772–773
labor and delivery, 782–783
macrosomia, fetal diagnosis of, 781–782
monitoring and treatment, 777–781
nephropathy, 777
ophthalmologic, 773–776
thyroid disease, 776
oral antihyperglycemic agents caution with, 756–757, 780
risks of, 771–773
type 1 considerations, 772, 776, 779–780
type 2 considerations, 772, 779–780
Graves' disease and, cautions with, 326, 329–330
screening recommendations for, 345–347
mild hypothyroidism with, as treatment indication, 406–407
thyroiditis with. See *Postpartum thyroiditis.*
Pretest probability, estimation of, 93–95
Primary hyperparathyroidism, arthropathies with, 461, 467
asymptomatic, bone densitometry indices of, 469–471
bone histomorphometry of, 471
clinical features of, 451, 468–469
National Institutes of Health guidelines for, 469, 471–472
surgical indications for, 469–472, 476, 489–491
cardiovascular disorders with, 460–461
classical (symptomatic), features of, 451, 456, 460, 466
surgical indications for, 466–468, 475, 489–490
clinical presentation of, 482–483
definitive therapy for. See *Parathyroidectomy.*
diagnosis of, 483–484
etiology of, 480–482
extracellular calcium-sensing receptor resistance with, 518–519
familial syndromes of, 467, 480–482, **503–522**
hypercalcemia with, 451–454, 466
treated vs. untreated, 454–455, 466–468
medical approaches to, **523–539**
bisphosphonates, 525–526, 530
calcimimetics, 530–535
estrogens, 526–530
for familial disorders, 507, 515
impact of, 452
phosphate, 524–525, 534
progestins, 526–530
with parathyroid carcinoma, 466, 523–524, 535
with parathyroid crisis, 535–536
MEN–1 with, 467, 480–481, 542–545
mortality of, 461
natural history of, **451–464**
biochemical features, 451–455
other clinical features, 460–461, 467
skeletal disease, 456–460
stone disease, 455–456
with and without surgery, 475–476
nephrolithiasis with, 455–456, 469
neuromuscular syndrome with, 460
neuropsychiatric disorders with, 460, 467–469
nonintervention of, impact of, 452, 475–476
surgery vs. nonsurgery, **465–478**
osteitis fibrosa cystica with, 456–460
persistent or recurrent, 495–496
surgical approaches to, **479–502**. See also *Parathyroidectomy.*
contraindications for, 507, 518
indications for, 489–491, 518
observation vs. operation, **465–478**
with parathyroid carcinoma, 466, 480–481, 483
Probabilistic diagnoses, 92
Probability, concept of, 92–93
estimation of, 93–95
updating of, 93–94, 98–99
17-OH-Progesterone (17-OHP), adrenal incidentalomas and, 112–113
Progestins, for primary hyperparathyroidism, 526–530
Prognostic diagnoses, 92
Programmed cell death. See *Apoptosis.*
Prolactin, overexpression of, in pituitary incidentalomas, 205–210, 212–213
screening tests for, 214–215, 227
Prolactinomas, 206, 210, 212, 216
in MEN–1 syndrome, 548
Proliferative diabetic retinopathy, 814–818
Protein-binding interactions, of drugs in diabetic patients, 791
Protein electrophoresis, serum, for hyperparathyroidism diagnosis, 484

Protein inhibitors, as apoptosis inhibitors, 377–378, 380
Protein metabolism, with diabetic ketoacidosis, 659
Protein reactivity, with adrenal neoplasms, 4–6, 16–17
Proteolytic enzymes, hypophosphatemia and, 595
Pseudohypohyperparathyroidism (PHP-HPT), 578–579
Pseudohypoparathyroidism (PHP), **596–589**
  clinical features of, 569–570
  from parathyroid hormone resistance, 571–574
  genetic variants of, future directions for, 584–585
    inheritance patterns of, 577–578, 581–584
    molecular evidence for, 569–570, 583–584
    phenotypic correlations, 577–578
  GNAS1 gene mutations in, evidence of, 576–579, 581–583
    exon ablation clues for, 583–584
  Gsa defects with, 569, 574–576, 579, 584
  mineral ion homeostasis and, 570–571
  pseudo (pPHP), gene mutations with, 576–578, 583
    Gsa activity with, 574–576
    inheritance patterns of, 577–578
    resistance basis of, 569, 574
  renal function and, 570–571, 584
  type Ia (PHP-Ia), gene mutations with, 569–570, 576–578, 583
    Gsa activity with, 574–576
    inheritance patterns of, 577–578
    resistance basis of, 569, 571–574
  type Ib (PHP-Ib), gene mutations with, 579, 581–583
    Gsa activity with, 579
    inheritance patterns of, 581–583
    resistance basis of, 569, 571, 578–579, 582–583
    severity variability of, 581–582
  type Ic (PHP-Ic), 569
  type II (PHP-II), 569–570
  without hormonal resistance, 574
Pulmonary function, diabetic ketoacidosis and, 661, 664–666

Quality-adjusted life-days (QADs), with adrenal incidentalomas, 74–83, 89–90
Quality-adjusted life-years (QALYs), cost-effectiveness analysis and, 89–90
  with adrenal incidentalomas, 74–83, 89–90
  with pituitary incidentalomas, 213–215, 228

Radioactive ablation therapy, for Graves' disease. See *Iodine ^{131}I therapy.*
Radiography, for hyperparathyroidism diagnosis, 466, 469–470
Radioisotopes, for Cushing's syndrome evaluation, 51–52
  for incidentaloma diagnosis, of adrenal gland, 33–34, 118–120, 129, 176, 178
  of thyroid, 189–190
Radiology. See also *Imaging techniques.*
  of adrenal glands, **27–42**
    incidentaloma discovery by, 1, 27, 57, 69, 127, 136–138, 141, 146, 160
    plain abdominal radiographs, 29
    preoperative indications, 58
    serial follow-up guidelines, 59, 121, 136–137, 153–154, 180
Radiotherapy, for Graves' ophthalmopathy, 297–299, 307–310, 312
    retrobulbar, 313–315
  for toxic nodular goiter, 351
  hypothyroidism from, 401
Ranitidine, for gastrinomas, 546
Rapid enzymatic methods, for ketone body measurement, in diabetic ketoacidosis, 711–712
Red blood cells, 2,3-diphosphoglycerate levels in, with diabetic ketoacidosis, 661, 670, 678
Renal failure, with hyperglycemic disorders, 660, 664, 670, 691, 699
Renal function, diabetic pharmacokinetic interactions and, 791–792
  hyperparathyroidism and, 455, 468, 472, 484
    as parathyroidectomy indication, 484, 496–497
    familial disorders of, 506–508, 513–514
  phosphate metabolism per, 591–593
  pseudohypoparathyroidism and, 570–571, 584
Renal insufficiency, glycemic control and, 738, 755
Renal phosphate wasting, 592–593
  genetics of, 594–599
    current models of, 598
    murine mice models of, 594–596
  treatment of, 602–603
Reperfusion therapies, for myocardial infarction, in diabetic patients, 836, 834–835
Representativeness heuristics, 93–94
Respiratory compensation, with diabetic ketoacidosis, 661, 664
Retinal deterioration. See *Diabetic retinopathy.*
Retinal occlusions, in diabetic patients, central artery, 818–819
  central vein, 819
Review bias, in diagnosing, 98

Rhinocerebral mucormycosis, in diabetic patients, 822–823
Rickets, hypophosphatemic, autosomal dominant, 597–598
hereditary, with hypercalciuria, 599–601
treatment of, 602–603
X-linked rickets, 593–597
vitamin D-dependent, type I (VDDR I), 617–619, 621–622
type II (VDDR II), 619–620, 622

Salicylates, for diabetic patients, hypoglycemia from, 798
Saline suppression test, for adrenal pathology, 115
Schwannoma, 144–145
Scintigraphy, of adrenal incidentalomas, 33–34, 148–149, 151, 176, 178
of adrenal masses, 129, 135
of Cushing's syndrome, 51–52
of thyroid incidentalomas, 189–190
Screening programs. See *Population screening*.
Self-management, of diabetes mellitus, on type 1 sick-days, 709–710, 717
rules for, 715–720
telephones resources for, 720, 734
Sensitivity, of tests, 96–99
Serum osmolality, with diabetic ketoacidosis, calculation of, 692
pathophysiology of, 664–665, 676, 688–689, 698–699
rapid shifts in children, 676–677
with hyperglycemic hyperosmolar nonketotic syndrome, 690
Sex hormones, from adrenal tumors, 20, 146, 168–169
Shock, with diabetic ketoacidosis, 664
Sick-day management, in type 1 diabetes mellitus, **707–723**
Silent ischemia, in diabetic patients, 832–833
Sipple's syndrome, 541
Skeletal changes, with hypophosphatemia. See *Rickets*.
with pseudohypoparathyroidism, 569, 571, 584
Skin abnormalities, parathyroid hormone–related protein and, 637–639
Sleep patterns, hypoglycemia and, 734–735
Smooth muscle regulation, parathyroid hormone–related protein and, 639
Sodium-dependent phosphate cotransporter, hypophosphatemia and, 594, 596, 598, 600
Sodium-hydrogen antiport plasma membrane transporter, in diabetic ketoacidosis, cerebral edema and, 676–680
Sodium imbalance, with diabetic ketoacidosis, 660, 664–665
replacement therapy for, 669–670
Sodium-iodide symporter (NIS), genetic encoding of, 390–392
hormone synthesis role, 389–390
in autoimmune thyroid disease, as autoantigen, 393–395
expression of, 392
regulation mechanisms, 392–393
Somatic symptoms, with mild hypothyroidism, as treatment indication, 405
Somatostatin analogues, for Graves' ophthalmopathy, 297, 314–315
for pancreatic tumors, 546–547
Somatostatinoma, in MEN–1 syndrome, 542, 547–548
Specificity, of tests, 96–99
Spectrum bias, in diagnosing, 98
Splenic injury, during adrenalectomy, 59–60
Spontaneous abortions, in diabetic women, 772–773
Spontaneous autoimmune thyroiditis (SAT), 360–361
Squamous carcinomas, hypercalcemia mechanisms with, 630, 638
Statistical analysis, in cost-effectiveness analysis, of adrenal incidentalomas, 89–90
Steroid-induced diabetes mellitus, 754, 756
Steroid synthesis inhibitors, for adrenal cancer, 21
Steroids, for Graves' ophthalmopathy, 297–299, 312–314, 331
glycemic control and, during hospitalization, 749, 756, 763–764
Streptozocin, for pancreatic tumors, 546–547
Stroke, anticoagulant therapies for, 765–767
glucose control with, 747, 750–752, 764–765
optimizing, 765–766
myocardial infarction with, 766–767
Substance abuse, hyperglycemia with, 691–692
hypoglycemia with, 738, 796
Sulfonylureas, for diabetic patients, 729–730, 736
during hospitalization, 755, 761
nonhypoglycemic reactions with, 805–806
pharmacokinetic interactions of, 791
names by generation of, 805
Surgery, exploratory, for parathyroidectomy localization, 484–485, 488–489
for hyperparathyroidism, bone mineral density and, 469–471, 490

bone remodeling and, 454–544
vs. nonsurgery, **465–478**
glucose control with, for coronary artery bypass surgery, 747, 750, 752
general, 750, 753–754, 759–760
of adrenal glands, **57–68**
Surgical excision, for tumor-induced osteomalacia, 603
of MEN–1 tumors, 546–548
Sympathomimetics, for diabetic patients, hyperglycemia from, 792–793

T lymphocytes, apoptotic pathways and, 376–378
in autoimmune thyroid disease, 287–288
in Graves' disease, 255–257, 259–261, 281
in Graves' ophthalmopathy, 287, 290–293, 309
in Hashimoto's disease, 365–366, 368
in postpartum thyroiditis, 425–426
receptor variable genes, 292–293
Teeth formation, parathyroid hormone–related protein and, 637, 639
Telephone services, for diabetes self-management, 720, 734
Test characteristics, interpretation of, 96–98
Test performance, evaluation of, 96–98
Tetany, with vitamin D deficiency, 612, 619
Thiazolidinediones, for diabetic patients, Cytochrome P450 enzyme interactions with, 799–800
during hospitalization, 755, 761
nonhypoglycemic reactions with, 808–809
Threshold probability, treatment, setting of, 95–96
Thrombolytic therapy, in diabetic patients, for myocardial infarction, 816, 831, 833–834
for stroke, 765–767
Thrombosis, with hyperglycemic disorders, 699–700, 767
Thymectomy, with parathyroidectomy, 494
Thyroglobulin (Tg), as autoantigen, 358, 363, 381–382, 389, 392–394
hormone synthesis role, 389–390
Thyroid autoantibodies. See also *specific antigen.*
family of, 339, 392, 395
postpartum, 422–426
Thyroid cancer, aberrant, 197–199
clinical significance of, 192–197
diagnosis of, 193–196
lateral, 197–198
management of, 194
natural development of, 197
nodal metastasis of, 194, 197–199
occult, 193–194
Graves' disease and, 332–333, 348
prevalence of, 194–195
risk factors for, 199–201
Thyroid cell apoptosis, in thyroid autoimmunity, new understanding of, **375–388**
Thyroid disease. See also *specific disease.*
age-specific hazard rates for, 242–243
autoimmune. See *Autoimmune thyroid disease.*
cognitive function and, 405, 407, 423
drug-induced, 401–402
epidemiology of, 241–244
eye disease from, onset of, 308–309
iatrogenic, 350
with gestational diabetes, 776
Thyroid function, fluctuation of, anti-TSH receptor antibodies and, 349–350
Thyroid function tests, 227. See also *specific hormone or test.*
diagnostic, sodium-iodide symporter dependent, 390
screening, for mild hypothyroidism, 409, 418
in older women, 240, 250
postpartum, 427–428
recommendations for, 249–250
Thyroid gland, apoptosis pathways in, 379–380
with autoimmune disease, 380–383
Thyroid hormone, replacement indications for, with mild hypothyroidism, 399
synthesis of, key aspects of, 389–390
Thyroid incidentalomas, **187–203**
benign, 192–193, 200
clinical significance of, 192–197
diagnosis of, autopsy examinations, 188–189, 192, 194
Bayesian approach example, 101–102
computerized tomography, 189–190, 196
fine-needle aspiration biopsy, 192, 194–197, 201
magnetic resonance imaging, 189–190
palpation method, 188–189
scintigraphy, 189–190
ultrasonography, 187, 189–193, 195
malignant. See *Thyroid cancer.*
management of, 198–201
nodule classifications, 192–193
overview, 187–188
prevalence of, 188–189, 194–195, 200
Thyroid peroxidase (TPO), as autoantigen, 339, 341, 351, 381–382, 392, 394
in Hashimoto's disease, 357–358, 363
postpartum, 423
hormone synthesis role, 389–390
Thyroid rest, lateral, 197–198
Thyroid-stimulating antibody (TSAb), in anti-TSH receptor assays, 340

Thyroid-stimulating antibody (TSAb) *(Continued)*
Graves' disease applications of, 341, 344, 346–348
in miscellaneous disorders, 348–351
Thyroid-stimulating hormone (TSH), hormone synthesis role, 389–390
levels, disease interpretations of, 242–244, 325–326
in mild hypothyroidism, 399–400, 402–403
postpartum, 418–419, 421
overexpression of, in pituitary incidentalomas, 205, 207–208, 227
tests, benefits analysis, 248–249
predictive values of, 245–246
Thyroid-stimulating hormone-binding inhibitory immunoglobulin (TBII), in anti-TSH receptor assays, 340
Graves' disease applications of, 341–342, 344, 346–348
in miscellaneous disorders, 348–350
in sodium-iodide symporter assays, 394
Thyroid-stimulating hormone receptor (TSHR), a-subunits of, 268–269, 277–280
activation mechanisms of, 273–275
antibody probes for, 275–276, 280
as autoantibody target. See *Anti-TSH receptor antibodies.*
b-subunits of, 268–269, 277–280
cleavage mechanisms of, 278–279
connecting loops of, 270–271
ectodomain inserts of, 270
extrathyroidal expression of, 281–282
with Graves' disease, 347–348
functional maturation of, 279
functional studies of, 272–273
in Graves' disease, 255, 259–261
genetic encoding of, 269, 272–273
glycosylation process of, 276–277, 279
immunology of, 255, 259–261, 267, 280–284
in Graves' disease, as major antigen of, 267, 280–283, 289
functions of, 255, 259–261
mouse models of, 282–283, 290–291, 440
multimeric forms of, 279–280
mutations of, 269, 272–273, 275
web site catalogue of, 273
N-linked sugars and cleavage in, 279
new insights into, **267–286**
physiology of, 267–269
recombinant expression of, 270, 273
splicing variants, 280
structural maturation of, 276–277
structural modeling of, 268–269, 275
transmembrane helices of, 270–271
Thyroid-stimulating immunoglobulins (TSI), in Graves' disease, 288, 325, 329, 332
Thyroid storm, management of, 327, 331–332
Thyroid tumors, in MEN–1 syndrome, 542–544, 551
Thyroidectomy, bilateral subtotal vs. Hartley-Dunhill operation, 328–329
for Graves' disease, indications for, 327–329, 345
total, for medullary cancer, 494
total vs. subtotal, 327–328
Thyroiditis, autoimmune, 348–350, 359–361
chronic lymphocytic. See *Hashimoto's disease.*
painless, 350, 358
post-pregnancy. See *Postpartum thyroiditis.*
postabortion, 426–427
subacute, 351, 434
Thyrotoxicosis. See also *Graves' disease.*
apathetic, 324
clinical manifestations of, 323–324
history of, 322–323
Thyrotropin. See also *Thyroid-stimulating hormone receptor.*
for gestational diabetes, 776
Thyroxine (T_4), as treatment, indications for, 241–242, 246
hormone synthesis role, 389–390
levels, disease interpretations of, 241–242, 246
in mild hypothyroidism, 400, 402–403, 407–408
Tissue plasminogen activator (tPA), for myocardial infarction, 833–834
for stroke, 765–767
Total parenteral nutrition (TPN), glucose control with, 762–763
Transaminase levels, alpha-glucosidase inhibitors impact on, 808
Transforming growth factor beta (TGF-b), breast cancer metastasis and, 631
Transmission disequilibrium test (TDT), in allele analysis, 258
Treatment threshold probability, setting of, 95–96
Triiodothyronine (T_3), hormone synthesis role, 389–390
levels, disease interpretations of, 242, 246
in mild hypothyroidism, 403, 408
Trisomy 21, thyroid disease and, 249, 363
with gestational diabetes, 782
True negative rate (TNR), of tests, 96–99
True positive rate (TPR), of tests, 96–99
TSHR gene, in Graves' disease, 255, 259–261

Tubular maximum reabsorption of phosphate per glomerular filtration rate (TMP/GFR), 592–593, 599, 602, 604
Tumor calcinosis, hyperphosphatemia from, clinical features of, 592, 603–604
genetics of, 604–605
management of, 605
Tumor-induced osteomalacia (TIO), clinical features of, 601–602
pathogenesis of, 602
renal phosphate wasting with, 592, 596
Tumor necrosis factor receptor (TNFR), in thyroid apoptosis, 293, 376–377, 392
Tumor necrosis factor-related, apoptosis-inducing ligand (TRAIL), as apoptotic pathway, 377–378
in thyroid, 379, 382–383
Tumor suppressor genes, adrenal incidentalomas and, 8–9
in adrenal cancer, 17–18
Tumors. See also *specific anatomy or type.*
Knudson's development model of, 551, 554–555
Turner's syndrome. See *Gonadal dysgenesis.*
Type 1 diabetes mellitus, glucose counterregulation in, 727–730
Graves' disease association with, 256, 278, 298, 438
Hashimoto's disease association with, 360, 364–365, 367
hypoglycemia with, 725–726, 728–729, 731, 737
hypothyroidism association with, 407
ketoacidosis with, 657, 683, 685. See also *Diabetic ketoacidosis.*
ketone body monitoring with, 710–714
management of, during hospitalization, 754, 756–757, 759–760, 763
long-term goals for, 657–658
sick-day focus for, 709–710, 715–720
onset of, in children, 657
postpartum thyroiditis association with, 420, 427
pregnancy with, 772, 776, 779–780
sick-day management in, **707–723**
blood sugar monitoring, 717
blood vs. urine monitoring, 711–714
cornerstones of, 715
demographics of, 708–709
fluid therapy, 716–718
hypoglycemia prevention, 716–717
insulin therapy, 715–716, 718–719
ketosis monitoring, 711–714, 717–718
medical team contact, 720
risks of, 707–710, 719–720
settings for, 709–710, 720
underlying triggers, treatment of, 719–720
Type 2 diabetes mellitus, endogenous insulin release in, 728
glucose counterregulation in, 727–730
hyperglycemia with, 661, 683, 685–686. See also *Hyperglycemic hyperosmolar nonketotic syndrome.*
hypoglycemia with, 725–726, 728–729, 736–737
management of, during hospitalization, 754–757, 762
onset of, in children, 657
pregnancy with, 772, 779–780

Ultrasonography, evolution of, 160
for fetal surveillance, with gestational diabetes, 781–782
for fine-needle aspiration biopsy (US-FNA), 35, 119, 192, 194–197, 201
for parathyroidectomy localization, 485–486, 489, 495
intraoperative, with adrenalectomy, 29, 61
of adrenal masses, 20, 29, 135
of thyroid incidentalomas, 187, 189–193, 195
Ultraviolet light exposure, vitamin D deficiency and, 613
Uncertainty, diagnostic, approach to minimizing, 91–93
Uric acid levels, with hyperparathyroidism, 484
Urinary calcium levels, diagnostic studies for, 468, 483–484
with primary hyperparathyroidism, decreased. See *Familial hypocalciuria hypercalcemia.*
elevated. See *Hypercalciuria.*
with secondary hyperparathyroidism, tissue-selective calcium resistance and, 518–519
Urinary glucose levels, with diabetic ketoacidosis, 659–660, 711
Urinary ketone levels. See *Ketonuria.*
Urinary metabolites, screening tests for, with pheochromocytomas, 116, 149

Validation techniques, for diagnoses, 95
Value bias, in diagnosing, 95
Vanillylmandelic acid (VMA), with pheochromocytomas, 100–101, 116, 149
Vascular complications, of diabetes mellitus, cardiac. See *Myocardial infarction.*
cerebral, 747, 750–752, 764–767
ocular, 818–821, 833
Vasopressin, adrenal incidentalomas and, 6
Venography, adrenal evaluations by, 33, 35
Venous catheterization, selective, for parathyroidectomy localization, 488, 495

Verner-Morrison syndrome, 547
Vertebral osteopenia, with hyperparathyroidism, 458–460, 473–474
VIPomas (vasoactive intestinal peptide-secreting pancreatic tumors), in MEN–1 syndrome, 542, 547
Viral infections, ocular, in diabetic patients, 823–825
Virilizing tumors, 20, 146, 168–169
Viruses, as apoptosis inhibitors, 378
Vision loss, in diabetic patients, 815–816, 818–819, 821
Visual field defects, with pituitary incidentalomas, 208–209, 214–215, 227, 229
Vitamin D, bone mineralization and, 591–592, 614
  cutaneous synthesis of, 611, 613
  dietary sources of, 611, 613
  for hypophosphatemic rickets, 603
  toxicity of, 615–616
Vitamin D deficiency, **611–627**
  at-risk populations for, 613–614
  causes of, 611–612
  clinical features of, 612, 614–615
  diagnosis of, 612, 615–617
  drug-related, 617
  prevalence of, 613–614
  risk factors for, 613–614
  treatment of, 615–617, 620–623
  with hyperparathyroidism, 453, 474–475
Vitamin D-dependent rickets, type I (VDDR I), 617–619, 621–622
  type II (VDDR II), 619–620, 622
Vitamin D metabolism, inherited abnormalities of, 617–620
  steps in, 611, 613
Vitamin D resistance. See *Vitamin D deficiency.*
Vitamin D supplements, for vitamin D deficiency, 615–616, 621–623
Vitrectomy, for diabetic retinopathy, 817
Vitreous hemorrhage, with diabetic retinopathy, 816–817
Vocal cord paralysis, from parathyroidectomy, 491
Volpé, Robert, on autoimmune thyroid disease, **431–442**
Vomiting, type 1 diabetes sick-days and, 716, 718, 720
  with diabetic ketoacidosis, 659–660, 662–664
  management of, 668–670, 675

Warfarin, for stroke, 767
WDHA (watery diarrhea, hypokalemia, hypochlorhydria) syndrome, 547
Web sites, for *PHEX* gene, 596
  of thyroid-stimulating hormone receptor mutations, 273
Wermer's syndrome, 541
Willingness-to-pay threshold, 90
Wound infections, glucose control with, 747, 750, 753–754

X-linked hypophosphatemic rickets (XLH), clinical features of, 593–594
  genetics of, murine models, 594–595
  PHEX codes, 594–597

Zollinger-Ellison syndrome, in MEN–1 syndrome, 545